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Prognosis of patients with acute myeloid leukemia (AML) remains 
poor despite the use of first-line induction chemotherapy. Therefore, it is 
imperative to find effective treatment for AML patients. The heterogeneous 
pathogenesis and molecular genetics of AML suggest that combination 
therapy may remain superior to any single agent. Safingol and C2-ceramide 
are promising bioactive lipids with activity against leukemia, and combining 
them to target various aberrant biological processes of AML may further 
improve therapeutic activity. However, the hydrophobicity and hemolytic 
toxicities of these bioactive lipids limit their potential to be translated to 
clinical use. Also, it is important to capture the potential synergistic effect that 
exists among the two lipids in order to achieve maximum therapeutic effect in 
AML. This thesis first presents the development of liposomes containing 
single bioactive lipid safingol, followed by the development of a liposomal 
formulation that incorporates safingol and C2-ceramide at a synergistic molar 
ratio for the treatment of leukemia to overcome the aforementioned challenges. 
Although the transmembrane pH gradient has been commonly used to load 
lipophilic amine drugs into liposomes, the presence of such gradient has 
completely abolished the biological activity of liposomal safingol. A positive 
zeta potential, which influenced cellular accumulation of liposomal safingol, 
was crucial to the anti-leukemic activity. Liposomal safingol was effective 
against a wide range of AML subtypes with minimal hemolytic toxicity, and 
was able to extend the median survival time of the U937-inoculated mice. The 
1:1 molar ratio of safingol and C2-ceramide was identified to be synergistic 
against a wide range of AML cell lines. Four cell cycle-related genes, 
 ix 
 
including PRMT5, Cdc25A, MYC and MYCBP, were found to be responsible 
for the synergism of the bioactive lipid combination therapy in AML cells. It 
is proposed that safingol/C2-ceramide combination could induce down-
regulation of these cell cycle-related genes which leads to an increase in p53-
mediated apoptosis. Next, a liposomal formulation that incorporates safingol 
and C2-ceramide at the synergistic 1:1 molar ratio was developed. The 
incorporation efficiency of the liposomes approached 100%, and the 
liposomes were stable over a 7-day storage period at 4ºC as defined by the 
drug content, size and polydispersity. The results also highlighted that 
liposome incorporation was able to significantly attenuate the hemolytic 
toxicities of the free form of safingol and C2-ceramide. A high performance 
liquid chromatography tandem mass spectrometry (LC/MS/MS) method was 
developed for the simultaneous determination of safingol and C2-ceramide in 
murine plasma. From the pharmacokinetic study in mice, liposomal 
safingol/C2-ceramide incorporated formulation could maintain the synergistic 
molar ratio of the bioactive lipid combination in plasma over 24 h. Of note, 
liposomal safingol/C2-ceramide had significantly enhanced the survival of the 
U937-inoculated mice despite 1.5-fold reduction in drug dose. More 
importantly, leukemic cells in peripheral blood (PB) and bone marrow (BM) 
were completely eliminated, with the restoration of normal WBC counts in 
mice treated with liposomal safingol/C2-ceramide. Taken together, the results 
from this thesis provide the basis for developing liposomal formulation for 
novel bioactive lipid-based combinations that have great potential for the 
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Chapter 1. Introduction 
In recent years, liposome drug delivery system has successfully 
encapsulated chemotherapeutic agents that ameliorated drug-related toxicity 
issues, while enhancing the overall therapeutics activity in cancer patients. The 
goal of this thesis is to develop and characterize a liposome delivery system that 
incorporates two bioactive lipids, safingol and C2-ceramide, at the synergistic 
molar ratio against AML, a deadly hematological malignancy. 
 
1.1.Hematological malignancies 
Hematological malignancies are cancers of the blood, bone marrow, and 
lymph nodes, which were first described by Thomas Hodgkin in 1832 in the 
medical literature[1]. In 2007, there were more than 119,724 cases of blood, bone 
marrow, or lymph node cancers diagnosed in the United States, and nearly 54,999 
people died from these cancers[2]. Hematological malignancies are a 
heterogeneous group of diseases of diverse etiology, incidence, and prognosis that 
are broadly divided into leukemia, lymphoma and myeloma. Leukemia is a cancer 
of the bone marrow and blood. It is classified into two main types, lymphocytic 
leukemia which involves an increase of lymphocytes; and myeloid leukemia 
which involves an increase in granulocytes. Lymphoma is a type of cancer that 
starts in the lymph system, and is classified as Hodgkin or non-Hodgkin 
lymphoma. The classification of lymphoma is based on the types of lymphocytes 
involved, and these two types of lymphomas behave, spread, and respond to 
treatment differently. Hodgkin lymphoma is characterized by the presence of 
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Reed-Sternberg cell, and it usually spreads to other lymph nodes in an organized 
and systematic fashion[3]. On the other hand, non-Hodgkin lymphomas begin 
when the B cells or T cells in the immune system begin to grow abnormally and 
spreads randomly through the lymph nodes[4]. Lastly, myeloma is a cancer of the 
plasma cells, where the cells overgrow and form a mass or tumor that is located in 
the bone marrow[5]. Subsequently, overgrowth of plasma cells will crowd out 
normal blood cells in the bone marrow and interfere with normal bone cells, 
leading to anemia, infection, easy bleeding and weak bones that are easily 
fractured.  Survival rates vary substantially by the types of hematological 
malignancies, ranging from 5-years relative survival of 39% for patients 
diagnosed with myeloma to 69% for those with non-Hogkin lymphoma[6]. 
According to Cancer Facts & Figures 2011, leukemia is the most deadly 
hematological malignancies with an estimation of 21780 deaths, accounting for 
about 41% of hematological malignancies-related deaths in 2011[6].   
 
1.2. Leukemia 
Leukemia, the most common blood cancer, is defined as cancer that starts 
in blood-forming tissue such as the bone marrow, and causes large numbers of 
blood cells to be produced and enter the bloodstream. In a healthy person, most 
blood cells develop from hematopoietic stem cells in the bone marrow, by a 
process known as hematopoiesis (Figure 1). These hematopoietic stem cells 
divide and develop into myeloid stem cells or lymphoid stem cells. Subsequently, 
the myeloid stem cell develops into a myeloblast, megakaryoblast or 
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proerythroblast, while the lymphoid stem cell develops into a lymphoblast. 
Proerythroblasts, megakaryoblasts and myeloblasts will develop into red blood 
cells (RBC), platelets and certain types of white blood cells (granulocytes), 
respectively. On the other hand, lymphoblasts will develop into another type of 
white blood cell  known as lymphocytes. Each type of blood cells has its own 
different and essential function in the body. White blood cells are part of the 
immune system and play a key role in defending the body against foreign 
invaders during an infection. RBC play a key role in transporting oxygen and 
carbon dioxide between the lungs and the tissues. Platelets are instrumental in 
blood coagulation, the process by which the body prevents blood loss through the 
formation of blood clots. 
 
 
Figure 1. Hematopoiesis or blood formation. Adapted from [7]. Blood cells are 
mostly developed from cells in the bone marrow known as the blood stem cells.  
 
Platelets 
Blood stem cell 
Lymphoid stem cell Myeloid stem cell 
Myeloblast Lymphoblast 
White blood cells Red blood cells 
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In a person with leukemia, bone marrow will produce abnormal blast cells 
which will not become healthy white blood cells. These abnormal white blood 
cells, also known as leukemia cells can accumulate in the bone marrow, and 
healthy white blood cells, RBCs and platelets will be displaced by increasing 
numbers of the leukemia cells. Therefore, infection, anemia, or easy bleeding may 
occur. The leukemia cells can also metastasize to other parts of the body, 
including the central nervous system (brain and spinal cord), skin, and gums. 
Leukemia can be acute or chronic. Generally, acute forms of leukemia 
progress rapidly, while chronic forms of leukemia progress slowly. The four 
major types of leukemia are AML, chronic myeloid leukemia (CML), acute 
lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). The most 
common type of leukemia is CLL, accounting for 33% of the total estimated 
number of new leukemia cases in the United States on 2011, followed by 29%,  
13% and 12% for AML, ALL and CLL, respectively [8]. 
 
1.2.1. Acute myeloid leukemia 
AML is also known as acute myelocytic leukemia, acute myelogenous 
leukemia, acute granulocytic leukemia and acute non-lymphocytic leukemia. 
AML are blood cancer that starts in the precursors of myeloid cells. As AML 
progresses, these immature blasts will crowd out the normal cells in the marrow 
and leads to the infection, anemia and easy bleeding. AML progresses rapidly and 
is typically fatal within weeks or months if left untreated. AML accounts for 
about 29% of all leukemia, with approximately 12,950 people will be diagnosed 
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with AML in 2011, and 9,050 patients will die from the disease in the United 
States [8]. The incidence and mortality rates for leukemia have decreased slightly 
over the last 20 years but the outlook of the patients remains poor especially for 
elderly patients, with a 5-year survival of <5% in those over 65 years [9].  
Although the root cause of AML is not known, several factors are 
associated with an increased risk of the disease. The risk of AML increases with 
age. AML is most common in adults 65 years of age and above. People exposed 
to very high levels of radiation, such as survivors of a nuclear reactor accident or 
atomic bomb blast, will have an increased risk of developing AML[6]. Exposure 
to certain chemicals, such as benzene, which is found in unleaded gasoline, 
cigarette smoke and many chemical industries, increases the risk of developing 
AML[6]. Secondary AML is more likely to occur in patients with other cancers 
who are treated with certain chemotherapeutic drugs, particularly in patients 
treated with combination of radiation and chemotherapy [10]. Certain genetic 
disorders, such as Down syndrome and Fanconi anemia, are associated with an 
increased risk of AML[11]. Also, patients with certain blood disorders are at 
increased risk for getting AML, including myelodysplastic syndrome, 
polycythemia vera, essential thrombocythemia[11]. Moreover, patients who have 
myelodysplastic syndrome and develop AML typically have poor prognosis[11].  
AML are classified by the pathologists using two different systems, 
French American British (FAB) and the newer World Health Organization (WHO) 
classification. The FAB classification is based on morphology relying on 
cytochemical stains and incorporates flow cytometry to define an 
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immunophenotype which separates myeloid from lymphoid blasts[12]. There are 
eight subclasses of AML categorized based on degree of differentiation, as shown 
in Table 1. Although the FAB system is still in use, the WHO classification is the 
preferred system (Table 2). The WHO system was designed to include prognostic 
factors, chromosome translocations, and evidence of dysplasia either by 
morphology or history which might predict biological responsiveness, allowing 
physicians to identify subgroups of patient who might benefit from specific 
treatment strategies[12, 13]. Diagnosis of AML is established by the presence of 
≥30% and ≥20% myeloblasts in blood and/or bone marrow according to the FAB 
and WHO classification, respectively [13].  
During the initial evaluation of the patients, the disease-specific factors, 
such as prior toxic exposure, myelodysplasia and karyotypic or molecular 
abnormalities which may provide prognostic information that may have an impact 
on responsiveness to chemotherapy and risk of relapse will be characterized[14]. 
Also, patient-specific factors including co-morbid conditions that may affect an 
individual’s ability to tolerate chemotherapy will be taken into consideration for 











M0 Undifferentiated acute myeloblastic leukemia 5 
M1 Acute myeloblastic leukemia with minimal 
maturation 
10 
M2 Acute myeloblastic leukemia with maturation 30-45 
M3 Acute promyelocytic leukemia  5-8 
M4 Acute myelomonocytic leukemia 15-25 
M5a Acute monoblastic leukemia 5-8 
M5b Acute monocytic leukemia 3-6 
M6 Acute erythroid leukemia 5-6 
M7 Acute megakaryoblastic leukemia 3-5 
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• Acute myeloid leukemia with t(8;21)(q22;q22), 
(AML1/ETO)   
• Acute myeloid leukemia with abnormal bone marrow 
eosinophils and inv(16)(p13q22) or t(16;16)(p13;q22), 
(CBFβ/MYH11)   
• Acute promyelocytic leukemia with t(15;17)(q22;q12), 
(PML/RARα) and variants  





• Following MDS or MDS/MPD    
• Without antecedent MDS or MDS/MPD, but with dysplasia 






• Alkylating agent/radiation–related type 
• Topoisomerase II inhibitor–related type (some may be 








• Acute myeloid leukemia, minimally differentiated     
• Acute myeloid leukemia without maturation     
• Acute myeloid leukemia with maturation     
• Acute myelomonocytic leukemia     
• Acute monoblastic/acute monocytic leukemia 
• Acute erythroid leukemia (erythroid/myeloid and pure 
erythroleukemia) 
• Acute megakaryoblastic leukemia 
• Acute basophilic leukemia     
• Acute panmyelosis with myelofibrosis     
• Myeloid sarcoma 
 
Treatment of AML is divided into two phases: induction and post-
remission [15]. Induction therapy is aimed to reduce leukemic burden maximally 
in order to restore normal hematopoiesis. Currently, combination chemotherapy is 
the primary treatment modality for patients with AML. The “3+7” regimen, which 
combines a seven-day continuous intravenous infusion of cytarabine with a short 
infusion or bolus of an anthracycline given on days one through three, has been 
the standard of care for induction therapy of AML for more than 40 years[16] 
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(Table 3). The most common induction regimen used for patients with AML is the 
standard cytarabine plus daunorubicin regimen. While successful induction 
therapy virtually eradicates the leukemia cells in bone marrow and restores 
hematopoiesis in patients, post-remission therapy, also known as consolidation 
therapy, is needed to destroy leukemia cells that have survived induction 
chemotherapy but are undetectable by conventional means. Without consolidation 
therapy, virtually all of these patients will relapse within a median of four to eight 
months[17]. There are three options available for post-remission therapy: 
consolidation chemotherapy, autologous hematopoietic cell transplantation, 
and/or allogeneic hematopoietic cell transplantation. Consolidation chemotherapy 
with high dose cytarabine appears to provide the best survival for most patients 




Table 3. Overview of common induction therapy regimens for acute myeloid 
leukemia in patients under 60 years. Adapted from [16].  
 
CR rates for patients who are 60 years and younger have consistently been 
in the range of 70-80%, but most ultimately relapse and overall survival is only 
40-45% at 5 years [18]. More alarming, patients 60 years of age and above with 
AML have worse prognosis, with CR rates of 40% to 50% for those with a good 
performance status, but cure rate are less than 10% and median survival is less 
than 1 year [19-21]. Furthermore, substitution with other anthracyclines 
(doxorubicin, idarubicin, or mitoxantrone), increased the dose of cytarabine or 
daunorubicin, or addition of a third or fourth drug (fludarabine, etoposide, 
topotecan, thioguanine, or mitoxantrone) have not improved response rates of 
AML [22-25]. Moreover, several agents with initially promising results have 
failed to improve outcomes in randomized trials, including the P-glycoprotein 





Cytarabine: 100 to 300 mg/m2 
daily as a continuous infusion 
for 7 days; Daunorubicin: 60 to 
90 mg/m2 intravenous push on 
each of the first 3 days of 
treatment 
"Standard 7+3" induction 
regimen resulting in 
approximately 60 to 80 % 
remission rate and acceptable 





Cytarabine: 1 to 3 g/m2 twice 
daily for a total of 12 doses; 
Daunorubicin: 45 mg/m2 
intravenous push for 3 days 
following cytarabine 
Yields a 90 % remission rate; 
however, substantial toxicity 
precludes post remission 





Cytarabine: 100 to 200 mg/m2 
daily as a continuous infusion 
for 7 days; Idarubicin: 12 to 13 
mg/m2 IV push on each of first 3 
days of treatment 
Has produced a greater 
remission rate (88 versus 
70 %) than cytarabine/ 
daunorubicin in younger 
patients; appears superior to 
daunorubicin in patients with 
hyperleukocytosis; overall 
survival not clearly superior 
to "standard" regimen 
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modulator zosuquidar[26], the sulfonylhydrazine alkylator laromustine[27], and 
gemtuzumab ozogamicin[28].  
In summary, given that the prognosis of patients with AML remains poor 
despite the use of the first-line, anthracycline- and cytarabine-based induction 
chemotherapy, and many promising drug candidates have been withdrawn from 
the market or failed to improve outcomes in randomized trials, there is a pressing 
need to find effective new treatment for AML patients, especially for those who 
are >60 years.  
 
1.3. Sphingolipid as emerging anti-leukemia agent 
Current knowledge on cancer cell death and signaling has helped in the 
discovery of new and effective therapeutic strategies. Sphingolipids have emerged 
as the critical players in the leukemia arena over the past decades, as various 
studies have demonstrated their pivotal role in multiple cellular processes, such as 
apoptosis, cell proliferation, differentiation and chemoresistance [29-31]. A large 
body of evidence has demonstrated the potential of sphingolipids as drug 
candidates in the search of new anti-leukemic agents [32, 33]. Sphingolipids are 
amphipathic molecules with hydrophobic and hydrophilic properties (Figure 2). 
Sphingolipid is characterized by a sphingosine backbone, which consists of a 
polar amino group and a non-polar fatty acid chain. The amino group of 
sphingosine can be derivatized with a fatty acid chain to form ceramide, while the 
1-hydryoxyl group can be further conjugated with a polar headgroup to produce 
complex sphingolipids. Besides playing a structural role in regulating the fluidity 
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of cell membrane[34], sphingolipids are known to be involved in the pathogenesis 
of human disorders, such as cancer, inflammation, neurological, immune and 
metabolic disorder[34, 35]. Because of their key roles in mediating various 
cellular processes, sphingolipids belong to the group of bioactive lipids. The use 
of exogenously added bioactive lipids have been attempted to induce pro-
apoptotic signals. Ether lipids (such as miltefosine)[36, 37], ceramides (such as 
C6-ceramide)[38] and sphingosines (such as safingol)[39] are some examples of 
pro-apoptotic bioactive lipids. Each bioactive lipid has different mechanism of 
actions, depending on the type of cell line and concentration used. For instance, 
C6-ceramide was found to inhibit phosphorylated ERK, reduce survivin 
expression, and induce caspase-dependent apoptotic cell death in leukemic cells 
[40], while safingol was shown to induce necrotic cell death in a caspase-
independent manner through reactive oxygen species (ROS) generation in breast 




Figure 2. General structures of phospholipid, sphingolipid and cholesterol. 
Adapted from [42]. Different attachments of functional groups at R and R’ give 




Table 4 lists the examples of bioactive lipids that have advanced into 
various phases of clinical trial. More recent research has placed emphasis on 
ceramide and sphingosine-1-phosphate (S1P) due to their central role in the 
sphingolipid equilibrium (Figure 3). S1P is the product of phosphorylation of 
sphingosine by sphingosine kinase (SK). It has opposing effects on cell survival, 
with ceramide generally inducing cell death while S1P promoting cell 
proliferation. Since bioactive lipids play a critical role in regulating the survival of 
cells, it would be possible to treat leukemia by exploiting the pro-apoptotic effects 
and inhibiting the pro-survival effects of bioactive lipids. Safingol and C2-
ceramide are examples of SK inhibitor and ceramide analog, respectively, and the 




Figure 3. Sphingolipid rheostat. Adapted from [43]. The decision of cell death and 
survival can be affected by the balance between ceramide and S1P. SPPase: 





Table 4. Bioactive lipids as anti-cancer agents approved for clinical use or under 
clinical trials. 
Drug Dosage form Indication 
Current 
Status Significant outcome 





Miltefosine is an effective 
palliative treatment 
option for cutaneous 
metastases from breast 
cancer [44]. 








Phase III  
Perifosine in combination 
with capecitabine did not 
extend survival of 
patients with refractory 
advanced colorectal 
cancer, compared to 




good activity in renal cell 
carcinoma, 
neuroblastoma, non-small 







Edelfosine purging of the 
marrow gave a better 










Edelfosine did not extend 














Safingol in combination 
with cisplatin 
demonstrated good 











Topical treatment of C2- 
and C6- ceramide cream 
in a 1:1 ratio did not 
extend survival of 
patients with cutaneous 












ongoing No available data. 
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1.3.1. Safingol as a drug compound for the treatment of AML 
Safingol is a saturated, synthetic L-threo isomer of dihydrosphingosine 
[(2S, 3S)-2-amino-1,3-octadecanediol] that has completed a Phase I clinical trial 
recently [51]. Safingol has an 18-carbon hydrophobic aliphatic chain and a polar 
end consisting of a hydroxyl group and a basic primary amino group (Figure 4A). 
Safingol has demonstrated strong sphingosine kinase inhibition activity [53] and 
promising results as a chemopotentiating agent [54]. Potentiation is defined as the 
drug combination effect in which one of the two drugs is not effective by itself, 
but increases the effect of the other drug [55]. Safingol is a white or off-white 
crystalline solid with a molecular weight of 301.51. Safingol has limited aqueous 
solubility. On the other hand, it is soluble in ethanol with solubility of 7.5-8.2 
mg/mL. In the recently completed Phase I study, safingol was administered in an 
emulsion containing Lipoid 80 (Egg Phospholipids), dextrose, and lactic acid [51]. 
 
       
Figure 4. (A) Chemical structure of safingol. (B) Chemical structure of C2-
ceramide. Adapted from Avanti Polar Lipids. 
 
1.3.1.1. Therapeutic activities and mechanisms of action 
As a single agent, safingol has shown promising anti-leukemic activity in 
various human leukemia cell lines [29, 31]; yet, demonstration of its anti-
leukemic activity in animal models is still lacking. At the molecular level, 
(A) (B) 
Log P = 4.77 pKa = 9.29 
Log P = 4.39 
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safingol has been reported to act as a competitive inhibitor of SK, whereby it 
prevents the formation of S1P from sphingosine, which in turn inhibits cell 
proliferation, invasion and angiogenesis [51, 53, 56]. The accumulation of 
sphingosine may also increase endogenous ceramide level which would promote 
apoptotic cell death as described previously by Paugh et al. [57].  In addition, 
safingol has been demonstrated as a protein kinase C (PKC) inhibitor by acting on 
PKC regulatory domain and displacing phorbol dibutyrate from its lipid binding 
site [58].  As a result, PKC-regulated cellular processes, such as proliferation, 
differentiation, and invasion can be inhibited [59].  Interestingly, we and others 
found that PKC inhibition did not correlate with safingol cytotoxicity, as PKC 
was not inhibited with concentrations of safingol which could induce substantial 
cell kill [60, 61].  Instead, our data showed that ROS is an important mediator of 
safingol-induced cancer cell death in human breast and colon cancer cells, as well 
as mediating the synergism of safingol-based chemotherapeutic drug 
combinations [41, 62]. Synergism is defined as “the effect of two drugs in 
combination is greater than that achieved with either drug alone under identical 
treatment conditions”, provided that each drug alone has an effect [63]. 
Recently, safingol showed promising activity in refractory adrenocortical 
cancer when combined with cisplatin [51]. In addition, safingol could act as a 
potentiating agent that augmented the efficacy of other chemotherapeutic agents, 
including fenretinide, mitomycin-C, cytarabine and vinblastine in a variety of 
tumor cell lines [58, 64-69]. Several mechanisms underlying the potentiating 
effect of safingol in drug combinations have been proposed. Safingol has been 
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shown to potentiate cytarabine-induced apoptosis in leukemia HL-60 cells 
through inhibition of atypical PKC ζ and MAPK [67]. Similarly, it is proposed 
that inhibition of PKC by safingol potentiates mitomycin-induced apoptosis in 
gastric cancer cells [65].  In another study by Maurer et al., safingol demonstrated 
synergistic effect with fenretinide in neuroblastoma, lung, melanoma, prostate, 
breast, pancreas, and colon cancer cells, presumably through JNK/SAPK 
activation and increased ceramide generation [69]. 
 
1.3.1.2. Metabolism and toxicities 
In a pilot clinical study, safingol displayed a short half-life of 3.97 ± 2.51 h
in plasma with an estimated clearance of 3140 ± 765 mL/min and Cmax of                     
1040 ± 196 ng/mL at a dose of 120 mg/m2 [58]. In the Phase I study, the 
maximum tolerated dose (MTD) of safingol was determined to be 840 mg/m2 
when administered in combination with cisplatin. The mean Cmax and AUC of 
safingol at the MTD (840 mg/m2 of safingol) were 23.5 ± 6.5 µM and            
109.9 ± 16.1 µM•h, respectively[51]. Furthermore, this combination was found to 
be well-tolerated with no major increase in toxicities compared to cisplatin alone 
[51]. Dickson et al. reported that the principle dose limiting toxicity of safingol 
was reversible dose-dependent hepatic enzyme elevation [51]. Their results were 
in agreement with the findings of Morales et al. which showed elevated liver 
alanine aminotransferase in mice treated with safingol [70]. In addition, it was 
noteworthy that safingol caused intravascular hemolysis in preclinical rodent and 
canine models at the dose of 5 mg/kg and 20 mg/kg of safingol, respectively [54]. 
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Safingol was found to be preferentially N-acetylated by dihydroceramide 
synthase in liver microsomes to form dihydroceramide [71, 72]. Subsequently, 
dihyroceramide will be converted to an inactive metabolite, 
dihydrosphingomyelin [71]. In addition, Morales et al. also reported that safingol 
could be metabolized to form N-methylated derivatives, although the enzymes 
responsible for methylation of safingol are not known. Unlike N-acetylated 
derivatives, the mixture of N-methyl-, N,N-dimethyl- and N,N,N-
trimethylsafingol was only slightly less toxic than the unmodified safingol in 
mouse BALB 3T3 cells [70]. However, the toxicities of the individual N-
methylated metabolites have not been explored. 
  
1.3.2. C2-ceramide as a drug candidate for the treatment of AML 
Besides safingol, ceramides have also been identified as important 
bioactive lipids that mediate diverse range of cellular processes, such as cell 
differentiation, senescence, growth arrest or programmed cell death, in response 
to a large number of extracellular signals [73]. C2-ceramide, also known as N-
acetoyl-D-erythro-sphingosine, is a synthetic short-chain membrane-permeable 
ceramide analog, which has been widely used to mimic the actions of endogenous 
ceramides [38, 74, 75]. C2-ceramide has a long sphingoid base with 18 carbons 
linked to a 2-carbon fatty acid by means of an amide linkage (Figure 4B). 
Physically, C2-ceramide is a white to off-white crystalline solid with a molecular 
weight of 341.53. C2-ceramide is slightly soluble in water but it may precipitate 
from aqueous media, particularly those lacking serum albumin, at concentrations 
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of approximately 20 μM or higher. On the other hand, it is soluble in ethanol and 
DMSO with solubility of >25 mg/mL and >50 mg/mL, respectively. 
 
1.3.2.1. Therapeutic activities and mechanisms of action 
Ceramides have important role as regulators of cell functions, particularly 
in mediating growth suppression and apoptosis [34]. The production of 
endogenous ceramide is associated with numerous stress stimuli; thus, generation 
of ceramide has been proposed as a hallmark of apoptosis[76]. This contention is 
supported by several lines of evidence. First, many cytokines, environmental 
stress, ionizing radition and chemotherapeutic agents are known to initiate 
apoptosis associated with increased endogenous ceramide generation[77]. 
Secondly, treatment of cancer cells with ceramidase inhibitor will lead to an 
increase in ceramide levels and results in apoptosis[78], while apoptotic cell death 
following generation of ceramide by chemotherapeutic agent can be blocked by 
the ceramide synthesis inhibitor, fumonisin B1[79]. These observations imply that 
therapeutic approaches aimed at increasing intracellular ceramide levels could 
lead to an enhanced apoptotic response. Of note, addition of exogenous C2-
ceramide is able to increase the intracellular ceramide level, and induces apoptosis 
in many cell lines [76, 80]. Previously, C2-ceramide has been studied in a Phase 
II study of topical ceramides for refractory cutaneous breast cancer [52]. However, 
the results of the clinical trial were not sufficiently promising to merit further 
study of ceramides delivered by means of a topical cream, consisting of a mixture 
of C2- and C6-ceramides at 1:1 ratio. This could be possibly due to low 
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bioavailability of ceramides delivered by the topical cream. However, little is 
known about the formulation characteristics and pharmacokinetics of the topical 
ceramides cream which are important determinants of the anti-cancer efficacy. As 
a single agent, C2-ceramide was found to induce apoptotic cell death in numerous 
leukemia cell lines [74]. At the molecular level, exact mechanisms of ceramide-
induced apoptosis, including the nature of the targets and details of the 
downstream signaling cascades have not been fully elucidated. Ceramide-
activated protein phosphatase (CAPP) and ceramide-activated protein kinase 
(CAPK) have been implicated in transmitting the signals elicited by ceramide. 
Ceramide is known to activate CAPP which promotes growth suppression via 
dephosphorylation of the pro-growth cellular regulators PKCα, PKB, Bcl-2 and 
retinoblastoma protein Rb [81, 82]. Activation of CAPK by ceramide 
phosphorylates Raf-1, which in turn activates the MAPK pathway and eventually 
leads to inactivation of PKB that promotes Bad-triggered cell death[83]. 
Furthermore, C2-ceramide has been shown to induce formation of ceramide 
channel in the mitochondrial membrane which will result in the generation of 
ROS and induction of cytochrome c release [84-87], and subsequently leads to 
apoptotic cell death.  
Researchers have shown that C2-ceramide, in addition to its 
chemotherapeutic activity, could potentiate the anti-cancer activity of paclitaxel, 
CD95 ligand, prolactin blocking antibody and vesnarinone [88-91]. These 
potentiating effects may result from the reversal of multidrug resistance due to an 
increase in endogenous ceramide production. Although the mechanisms by which 
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C2-ceramide mediates these effects are not fully understood, these results have 
revealed the opportunities for ceramide to be exploited as a potentiating agent in 
combination with other chemotherapeutic agents. 
 
1.3.2.2. Metabolism and toxicities 
To date, metabolic pathway of C2-ceramide has not been well 
characterized. Nonetheless, C2-ceramide metabolism is likely to be regulated by 
activities of enzymes that synthesize and catabolize endogenous ceramide, as 
shown in Figure 5. Ardail et al. reported that C2-ceramide was found to be 
preferentially metabolized to C2-sphingomyelin by sphingomyelin synthase [92]. 
In addition, a small proportion of exogenous ceramides were converted to neutral 
glycolipids and gangliosides, possibly through the glucosylceramide synthase 
pathway. Other possible metabolic pathways for C2-ceramide include 
phosphorylation by ceramide kinase and deacetylation by ceramidase to form 
ceramide-1-phosphate and sphingosine, respectively.  
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Figure 5. Ceramide metabolic pathways. Adapted from [77]. 
 
 The toxicity profile of C2-ceramide has not been extensively studied. 
However, there is no significant toxicity observed in the Sprague-Dawley rat 
model treated with 50 mg/kg of C6-ceramide, a membrane permeable ceramide 
with 6-carbon N-acyl chain [40]. A possible toxicity of C2-ceramide would be 
intravascular hemolysis as the structure of ceramide resembles that of the 
amphiphilic and surface active detergent.  
Despite accumulating evidence suggesting the therapeutic potential of 
these sphingolipids as a single agent, combination therapy may be superior and 
more likely to deliver complete and lasting responses in AML, especially 
considering the heterogeneous pathogenesis and molecular genetics of AML. In 
order to obtain desired efficacy with minimum toxicity from drug combinations, it 
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is important that the drug combinations are designed with appropriate rationale. In 
the following sections, various approaches dealing with the design of drug 
combinations in cancer treatment will be reviewed.  
 
1.4. Rational design of anticancer drug combinations  
Combination-based chemotherapies have been the standard in the clinic to 
treat various types of hematological cancers and solid tumors, including AML. It 
is generally believed that combination therapy provides a higher chance of 
achieving a cure [93]. The concept of combination therapy was founded in 1965 
by Frei and co-workers [94]. Two fundamental principles have been formulated to 
guide the selection of anti-cancer agents that make up the drug combination. First, 
anti-cancer agents with different mechanisms of action that target different 
biological mechanisms of cancer are selected to minimize the development of 
drug resistance. Secondly, the anti-cancer agents should have non-overlapping 
toxicities so as to achieve maximum cancer cell kill with a tolerable level of 
toxicity by administering each of the agents at the MTD. However, patients 
treated based on this approach of MTD administration generally suffer a broad 
range of toxicities whereby dose reduction is often recommended. Moreover, 
several lines of clinical evidence suggested that the MTD approach could be more 
toxic and less effective in improving the overall survival of patients [95].  
Since MTD approach is associated with a number of issues, a new strategy 
is developed to attain maximal benefits from a particular combination therapy, 
that is, to capture the beneficial additive or synergistic interactions among the 
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individual anti-cancer agents such that maximum cancer cell kill could be 
achieved with lower doses of the individual agents. Several mathematical models 
have been developed to determine the synergistic, additive or antagonistic effect 
of a drug combination, and the two most widely used models are the isobologram 
method [96, 97] and the median effect principle [55]. 
In classical isobologram, a line known as the line of additivity, connects 
the two points which represents the concentrations of each agent to attain a 
specific effect (e.g. 50% cell killing) when used alone [98]. Similarly, the 
concentrations of each agent when used in combination to attain the same effect 
are plotted on the same graph. Synergism, additivity, or antagonism is indicated if 
this point is located below, on, or above the line of additivity, respectively. The 
isobologram method is easy to use, and synergism, additivity and antagonism can 
be easily visualized from the graph. However, it requires large amount of data in 
order to perform the analysis. In addition, the isobologram method is not able to 
quantify the extent of synergism and antagonism.  
The median effect equation is a general equation for dose-effect 
relationship which was derived through mathematical induction using hundreds of 
enzyme kinetic models [99, 100]. According to Chou and Talalay, the median 
effect equation states that:  
Fa
Fu
=  � D
Dm
�
m or  Log Fa
Fu
=  m log D –  m log Dm, 
where Fa= the fraction affected by the dose, Fu= the fraction unaffected (where 
Fu = 1- Fa), D= dose of the drug, Dm = median dose indicating potency, m = an 
exponent representing the shape of the dose effect curve and signifies the 
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sigmoidicity of the dose effect curve, which is determined by the slope of the 
median-effect plot. In order to obtain a quantitative measure to the effect of a drug 
combination, the data can be analyzed through computer software (CalcuSyn 
from Biosoft) that generates a parameter termed Combination Index (C.I.) that is 
calculated based on the following equation: 














IC +=  
This C.I. equation is based on the median effect equation, proposed by 
Chou et al. [55]. In this equation, D1 and D2 represent doses of drug 1 and drug 2 
used in the combination to give an effect of x%, and (Dx)1 and (Dx)2 represent the 
doses of drug 1 and drug 2 to give the same effect when used alone. Hence, C.I. 
values of <1, ~1 and >1 represent synergistic, additive and antagonistic outcome, 
respectively, for a particular two-component drug combination. The 
recommended symbols and descriptions for presenting the degree of synergism 
and antagonism are summarized in Table 5. Unlike the isobologram method, this 
median effect principle approach could be amenable to high throughput format 
using cell-based screening assays that measure cell viability after exposure to a 




Table 5. Recommended Symbols for Describing Synergism or Antagonism in 
Drug Combination Studies Analyzed with the Combination Index (C.I.) Method. 
Adapted from [102]. 
 
Recent studies have shown that the anti-cancer activity of a combination 
regimen is highly dependent on the concentration ratios of the individual drugs at 
the site of action [103]. Although the synergistic concentration ratios of anti-
cancer agents for a particular combination regimen could be easily identified 
through in vitro studies, it is important to realize that the inherently different 
pharmacokinetic profiles of the individual agents would determine the 
concentration ratios at the site of action, which in turn dictate the response to the 
drug combination. Hence, it is imperative to find ways to address the above issues 
associated with the combination therapy to promote maximum therapeutic effect 
from a particular combination therapy. One such strategy is the use of 
nanoparticulate drug delivery systems to coordinate the pharmacokinetics and 
synchronize the release of drugs to maintain the desired drug ratio at the site of 
Range of CI  Symbol  Description 
<0.1  +++++ Very strong synergism 
0.1-0.3  ++++ Strong synergism 
0.3-0.7  +++ Synergism 
0.7-0.85  ++ Moderate synergism 
0.85-0.90  + Slight synergism 
0.90-1.10  ± Nearly additive 
1.10-1.20  – Slight antagonism 
1.20-1.45 – – Moderate antagonism 
1.45-3.3 – – – Antagonism 
3.3-10 – – – – Strong antagonism 
>10 – – – – – Very strong antagonism 
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action. The following section will provide a brief overview of nanoparticulate 
drug delivery systems in the development of combination therapy. 
 
1.5. Nanoparticulate drug delivery systems 
Advances in the field of nanotechnology have culminated various 
nanoparticulate systems as drug delivery platforms for anti-cancer agents. These 
include liposomes, polymeric nanoparticles and dendrimers, each with its promise 
and success in cancer therapy [104]. Currently, several nanoparticle-based 
combination therapies have advanced into various stages of clinical trial, while 
many are undergoing preclinical development [105].   
Polymeric nanoparticles are typically consisting of amphiphilic diblock 
copolymers that self-assemble into micelles in aqueous solutions. Several 
approaches could be used to co-encapsulate multiple anti-cancer agents using 
polymeric nanoparticles. Firstly, the drugs could be encapsulated within the 
polymeric core during nanoparticle formation. One example is the development of 
a polyisobutylcyanoacrylate nanoparticles that co-encapsulates doxorubicin and 
cyclosporin A [106].  However, this relatively simple approach offered little 
control over the drug release kinetics, and >80% of the drugs were released from 
the nanoparticles within 5 minutes. Secondly, the drugs could be covalently 
conjugated to the polymer backbone before nanoparticle synthesis. Recently, 
gemcitabine and doxorubicin have been conjugated to N-(2-
hydroxypropyl)methacrylamide copolymers to form nanoparticles [107]. This 
method allows precise control over the molar ratios of different drugs during the 
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conjugate synthesis process. However, this method requires an environment-
sensitive or enzyme-specific drug-polymer linker that would allow the release of 
the covalently-conjugated functional moieties at the site of action. Also, the 
complex synthetic scheme might be relatively difficult to scale up to commercial 
production. 
  Dendrimers are highly branched, globular macromolecules with many 
arms emanating from a central core. Similar to polymeric nanoparticles, multiple 
anti-cancer agents could be co-encapsulated into dendrimers through passive 
loading method or conjugation to the multivalent surface of the dendrimers. For 
instance, Tekade et al. had successfully developed a poly(amidoamine) (PAMAM) 
dendrimer that co-encapsulated methotrexate and all-trans retinoic acid [108]. 
Methotrexate was loaded into the hydrophobic cavity while all-trans retinoic acid 
was encapsulated within the void spaces between the branches. Of note, the most 
commonly used PAMAM dendrimers are known to cause hemolysis in a dose, 
generation and time dependent manner. Although the hemolytic toxicity could be 
minimized by surface modification of dendrimers with polyethylene glycol (PEG) 
[109, 110], there are potential concerns regarding the use of dendrimers as the 
drug delivery system for bioactive lipids which are also known to cause hemolysis. 
Liposomes are spherical lipid envelops with an aqueous core enclosed by 
bilayer membranes. This unique structure allows liposomes to deliver hydrophilic 
agents in the interior aqueous core and hydrophobic agents solubilized within the 
hydrophobic lipid bilayer. Amongst the various nanoparticulate delivery systems, 
liposomes have been the most advanced in the development of fixed dose 
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combination product for cancer therapy, with two such products entering into 
Phase II/III clinical trials. Table 6 lists the examples of liposome formulations of 
conventional cytotoxic drug combination together with the current status of 
development. Liposomal cytarabine: daunorubicin (CPX-351) is the only 
nanoparticulate delivery system for combination therapy that has advanced into 
Phase III clinical trial. It has not only demonstrated the potential of liposome to 
deliver and maintain the synergistic concentration ratio of the individual drugs in 
vivo, but also highlighted the importance of synergism in therapeutic efficacy of a 
particular combination therapy [111]. More importantly, liposomes have been 
extensively studied as a promising drug delivery system for various bioactive 
lipids, including edelfosine[112], miltefosine[113] and C6-ceramide[40] to 
overcome the poor water solubility and attenuate the hemolytic toxicity. In view 
of these advantages, liposomes will be used as the drug delivery system for 
bioactive lipids and their combinations in this thesis. In the sections to follow, 
various aspects of the design of liposome systems for the delivery of bioactive 
lipids and combinations will be reviewed.  
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The therapeutic advantage CPX-
351 was associated with prolonged 
maintenance of synergistic drug 
ratios in bone marrow.  Currently 






CPX-1 was dramatically more 
active than the free drug cocktail 
of the two drugs.  Currently in 






CPX-571 was superior when 
compared to the free drug cocktail 






The liposomal cocktail 
demonstrated superior inhibition 
of tumor growth as compared to 
the free drug cocktail as well as 






The co-encapsulated liposomal 
formulation demonstrated 
improved cytotoxic activity when 




4:1 Breast  
tumor 
The results emphasize the 
importance of in vitro screening to 
determine if the drug combination 
would act synergistically before 






A stable liposome formulation 
developed for the delivery of a 
synergistic combination of two 
topoisomerase inhibitors.  
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1.6. Liposomes as a drug delivery system 
1.6.1. Components of liposomes 
1.6.1.1. Phospholipids  
Phospholipids, also known as glycerophospholipid, are the main building 
blocks of liposome that consist of a hydrophilic phosphate head group and 
hydrophobic fatty acid chains bridged together by a glycerol backbone. The 
general structure of phospholipid is illustrated in Figure 2 (Page 11). The distinct 
properties of each phospholipid are determined by its acyl chain and head group. 
The hydrophobicity of the acyl chain of phospholipids is determined mainly by 
the acyl chain length and degree of saturation, which in turn, dictates the rate of 
desorption of individual lipids species from the liposome membrane[114, 115]. 
This property is particularly important for the retention of hydrophobic drugs, 
such as bioactive lipids, whereby saturated long acyl chain phospholipids would 
improve drug retention within the lipid bilayer of the liposome.  
The surface chemistry of the liposome is dependent on the charge and 
degree of bulkiness of the head group of phospholipids used. Phosphatidylcholine 
(PC) is the most commonly used phospholipid in liposome formulation due to the 
fact that they are zwitterionic at physiological pH.  The surface charge of the 
liposome depends on the net charge on the polar head group. Liposomes 
incorporated with phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic 
acid (PA) or phosphatidylglycerol (PG) thus have a negatively charged surface, 
while PC and phosphatidylethanolamine (PE) based liposomes will have a neutral 
charged surface at physiological pH. 
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1.6.1.2. Cholesterol  
Cholesterol (CHOL) is another common constituent of liposomes (Figure 
2; Page 11). CHOL contains a four-membered sterol ring with a hydrocarbon 
chain and a hydrophilic hydroxyl group. This amphipathic property allows it to be 
incorporated into the bilayer membrane of liposomes. However, unlike 
phospholipids, CHOL does not form a bilayer when it is hydrated in an aqueous 
medium alone, but requires the presence of other bilayer forming lipids. Although 
the theoretical maximum amount of CHOL that can be incorporated into the 
liposome bilayer is 77 mol% based on lipid packing [116], usually, only up to 50 
mol% of CHOL is used in a PC based liposome due to the appearance of CHOL 
microcrystals at higher concentrations,. Incorporation of CHOL into liposomes 
has significant implications on the various properties of liposomes, both physical 
and biological, which will be further described in section 1.6.2 and 1.6.3, 
respectively. 
 
1.6.2.Physicochemical properties of liposomes 
This section will discuss a number of physicochemical properties of 
liposomes, including shape of vesicles and gel to liquid crystalline phase 
transition temperature. Also, the potential of varying lipid composition in 
modulating these physicochemical properties to achieve desired functional 




1.6.2.1.Shape hypothesis of lipid polymorphism 
The “shape hypothesis” states that the ability of lipids to adopt different 
polymorphic phases is related to the dynamic molecular shape assumed by the 
lipids, where lipids with cylindrical, conical, and inverted conical geometry would 
preferentially adopt the bilayer, hexagonal and micellar phase, respectively [117]. 
Table 7 illustrates the phase behavior adopted by the different lipids based on 
their molecular shape. Formation of these polymorphic phases is 
thermodynamically favored due to hydrophobic interactions among the lipid 
molecules [118].  
 
Table 7. Polymorphic phases and corresponding dynamic molecular shapes of 
component lipids. Adapted from [117]. 
 
Phase Molecular Shape Examples of lipids 
 


















Phosphatidicacid/ Ca2+ (pH <6) 
Phosphatidylserine (pH <4) 
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In general, lipid species with the highest concentration will predict the 
overall phase of the lipid membrane. For example, a combination of cylindrical 
and inverted cone shaped lipids, such as DSPC/DSPC-PEG2000 (95:5 mol%) will 
form bilayers in solution [119]. Interestingly, two non-bilayer forming lipids 
exhibiting complementary shapes can also be mixed together to form bilayer 
[120].  Furthermore, the polymorphic phases of lipids can be modulated by other 
factors including temperature, salt concentration and pH [116, 117].  
 
1.6.2.2. Gel-to-liquid crystalline phase transition 
Liposomes have a distinct phase transition from gel to liquid crystalline 
phase that occurs at a characteristic temperature which can be measured by 
differential scanning calorimetry (DSC), as illustrated in Figure 6. Gel-to-liquid 
crystalline phase transition temperature (Tc) is the critical temperature required to 
induce a change in the physical state of the lipid from gel to liquid crystalline 
phase. It is well known that length and saturation of the phospholipid’s acyl 
chains, head group composition, and CHOL content have significant impact on Tc. 
In general, factors that increase the packing of the lipid membrane would result in 
a higher Tc. For instance, a higher Tc would be observed with increasing 
hydrocarbon chain length (DPPC 41ºC> DMPC 23ºC), increasing hydrocarbon 
saturation (DSPC 55ºC> DOPC -20ºC) or reducing head group bulkiness (DPPE 
63ºC> DPPC 41ºC). At concentration more than 30 mol%, CHOL eliminates the 
gel-to-liquid crystalline phase transition, resulting in a highly ordered but liquid 




Figure 6. DSC curves of DPPC liposomes in the presence of different amounts of 
cholesterol. Adapted from [121]. 
 
1.6.3. Biological fate of systemically administered liposomes 
The success of liposomal formulations for the treatment of AML is highly 
dependent on their prolonged circulation longevity to eliminate leukemia cells in 
the bloodstream and bone marrow. However, liposomes would be exposed to 
numerous blood components, such as serum protein, which may destabilize the 
liposome leading to leakage of the encapsulated drugs and removal by 
mononuclear phagocytic system (MPS) [123-127]. The MPS is a group of cells 
responsible for the removal of foreign particles from the circulation, which are 
primarily found in the liver, spleen and bone marrow. Intravenous administration 
of liposomes leads to predominant uptake of liposomes within tissues containing 
these phagocytic cells [128, 129]. The following sections will discuss a number of 
factors that affect the circulation longevity of liposomes, including liposome dose, 





It is known that an increase in liposome dose will lead to an increased in 
the liposome circulation lifetimes. The increased in liposome circulation lifetimes 
is related to saturation of MPS cells or depletion of plasma opsonins [130, 131]. 
Plasma opsonins are serum components which promote the phagocytosis of 
foreign particles, such as liposomes by MPS cells. Besides liver, liposomes also 
accumulate in other MPS sites, such as spleen, bone marrow and lung when a 
high lipid dose is administered [132]. Interestingly, chronic administration of high 
lipid dose also impairs the ability of MPS cells to remove liposomes [133].  
 
1.6.3.2. Size  
Liposome size is an important factor that will affect the clearance of the 
liposomes.  Liposomes are classified into three categories according to size and 
lamellarity: multilamellar vesicles (MLV, 1-100 µm), large unilamellar vesicles 
(LUV, 50-500 nm), and small unilamellar vesicles (SUV, 25-40 nm). The site of 
clearance is dependent upon the liposome size. For example, liposomes >1 µm 
diameter will be mechanically trapped within the spleen [134] while 
liposomes >500 nm diameter will be rapidly removed by fixed macrophages and 
blood monocytes [131]. On the other hand, liposomes ≤80 nm could pass through 
the fenestrated endothelium of liver and taken up by macrophages and liver 
parenchymal cells [135]. Of note, LUV with an average diameter of 100-200 nm 
is generally known to have longer circulation half-life [136]. Moreover, the 
sinusoidal endothelium of bone marrow has fenestration or pores up to 150 nm 
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and a discontinuous basement membrane [137], which makes LUV with an 
average diameter of <150 nm the preferred liposome size for the delivery of anti-
cancer agents for AML. 
 
1.6.3.3. Lipid composition 
Varying lipid composition can have significant effects on the biological 
fate of liposomes. For example, inclusion of negatively charge lipids, such as PS 
and PA into liposomes will result in rapid blood removal, exhibiting short 
circulation time and high protein binding [123]. It has also been suggested that the 
removal of liposome may be mediated by MPS recognition of specific head 
groups, such as PS [138, 139]. In addition, surface modifications of liposomes 
with polymer, such as PEG have been commonly used to extend the circulation 
longevity and reduce MPS recognition[140]. However, it should be noted that 
addition of PEG to the surface of liposomes may affect the cellular uptake of the 
liposomes as a result of shielding of the surface charge on the liposomes [141].  
Inclusion of CHOL in liposomes could significantly alter the in vivo 
stability of liposomes. For instance, DSPC liposomes with 30-50% CHOL 
incorporated could exhibit an elimination half-life of 5- 6h. However, in the 
absence of CHOL, the liposomes will be rapidly eliminated from the circulation 
in the order of minutes [142]. CHOL can also stabilize liposome and prevent 
content leakage mediated by plasma lipoproteins and other proteins in the 
circulation, by preventing insertion of apolipoproteins into liposome membrane 
and lipid transfer from liposomes to lipoproteins [123, 125, 126, 143-145]. 
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1.7. Development of drug encapsulation methods  
It is important to realize that the method used for drug encapsulation is 
one major determinant in the drug release kinetics of the liposome, which in turn 
affects the response to a anti-cancer therapy [146]. Several important factors must 
be considered in the selection of appropriate loading method. First, the method 
should be straightforward and conceptually easy. Secondly, drug encapsulation 
efficiency should approach 100% and the drug would be retained within the 
liposome reasonably well. Thirdly, the drug should be able to be released from the 
liposome at the site of action. The drug encapsulation method can be classified 
into passive encapsulation method and remote loading method. 
For passive encapsulation method, hydrophilic drug is incorporated into 
liposome by addition of drugs to hydration buffer where the drug would be 
trapped in the aqueous core during liposome formation. On the other hand, 
hydrophobic drug is added to the lipid mixture during lipid film formation such 
that it is entrapped in the hydrophobic lipid bilayer. The efficiency of this method 
ranges from 10-50% for hydrophilic drug depending on the trapped volume and 
lipid concentration of the liposome, while encapsulation efficiency of close to 100% 
for hydrophobic drug could be achieved if there are favorable drug-lipid 
interactions and good solubility in the lipid bilayer.  
Remote loading method generally involves encapsulation of drug against 
the drug’s concentration gradient. This method utilizes a transmembrane proton 
gradient (pH gradient) to encapsulate lipophilic amines, such as doxorubicin and 
vincristine, into the aqueous core of liposome [147, 148]. In general, the pH 
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gradient across the bilayer of liposome can be established by three different 
approaches. First, liposomes are prepared in an acidic buffer, such as 300 mM 
citrate at pH 4 and the pH of exterior buffer of the liposome is then adjusted by 
titration or buffer exchange through column chromatography to generate the 
transmembrane pH gradient. Secondly, ammonium sulfate ((NH4)2SO4) is used to 
prepare the liposome, followed by the exchange of exterior solution to a solution 
of sodium chloride to establish a (NH4)2SO4 gradient. Due to the high 
concentration of NH4+ inside the liposome, NH4+ will dissociate into ammonia 
(NH3) and subsequently diffuses out of liposome owing to its high permeability, 
leaving behind one proton (H+) for every one NH3 lost. Thirdly, this method 
involves the use of divalent cation ionophores, such as calcimycin (A23187), and 
a transition metal ion solution to prepare the liposome [149-151]. The function of 
ionophores is to translocate a divalent cation for the exchange of two H+. For 
example, the liposomes can be prepared in a transition metal solution containing 
manganese sulphate buffer and the external buffer replaced by SHE buffer 
(containing sucrose, HEPES and EDTA) to generate the transmembrane 
manganese ion gradient. Subsequently, addition of ionophore A23187 would 
facilitate the exchange of manganese ion inside the liposome core for protons 
from the external SHE buffer, leading to the generation of a pH gradient [152, 
153] . Drugs with protonable functional groups, such as amines, in the 
unprotonated form, are able to enter into the liposome where they get protonated 
and precipitated within the liposome core. These remote loading methods rely on 
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the fact that the protonated drugs would not be able to diffuse out of the liposome 
once reached inside the liposome core.  
Besides pH gradient, transmembrane transition metal ion gradient has also 
been used to remotely load various drugs into the liposomes. This method is based 
on the ability of drugs with coordination sites to form complexes with the 
transition metal ions. Furthermore, this method can be used in combination with 
the pH gradient established by ionophores, in hopes of improving the 
encapsulation efficiency of drugs which are poorly loaded by pH gradient method 
alone. 
 
1.8. Chapter summary   
This chapter has provided background information on hematological 
malignancies and AML, in particular, on the challenges of treating AML and a 
lack of effective chemotherapies. Moreover, concept of drug combination with 
particular emphasis on the various issues associated with the use of bioactive lipid 
combination, including the need to maintain synergistic molar ratio of the drug 
combination in vivo has been discussed. Lastly, various aspects of liposome 
technology that are relevant to the design of liposome systems to deliver a 
synergistic bioactive lipid combination for the treatment of AML has also been 
reviewed. The next chapter will focus on the rationale, hypothesis and objectives 
of the thesis. 
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 Chapter 2.Thesis rationale, hypothesis and objectives 
 
2.1. Thesis rationale and hypothesis 
Safingol and C2-ceramide are promising bioactive lipids with activity 
against leukemia. Since C2-ceramide and safingol may act independently through 
different cellular pathways or different stages of the same pathway, combining 
these two bioactive lipids may target various aberrant biological mechanisms of 
AML and may represent a novel strategy to potentially improve the therapeutic 
response. Yet, several challenges are to be overcome in order to realize the 
therapeutic potential of such bioactive lipid combination regimen. These include 
the hydrophobic and hemolytic nature of these single aliphatic chained lipids. In 
addition, recent studies have shown that the anti-cancer activity of combination 
therapy is highly dependent on the concentration ratios of the individual drugs at 
the site of action, which in turn, is governed by the inherent pharmacokinetic 
profiles of the individual drugs [103]. To date, liposomal delivery represents a 
viable approach in overcoming the hydrophobicity and hemolytic toxicity of 
bioactive lipids such as edelfosine and miltefosine, which have structures similar 
to safingol and C2-ceramide [112, 154]. More importantly, liposome delivery 
system has been demonstrated to coordinate the inherently different 
pharmacokinetics of individual drugs, making it possible to maintain synergistic 
molar ratio after administration in vivo [103]. Furthermore, it is well recognized 
that an appropriately designed liposomal formulation is able to achieve increased 
systemic drug exposure and passive delivery to the bone marrow, so as to 
eliminate leukemia cells in the bloodstream and bone marrow [155]. Hence, the 
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hypothesis of this project is that an appropriately designed liposome can 
efficiently incorporate safingol and C2-ceramide to facilitate the delivery of this 




The overall objective of this thesis is to develop a liposomal formulation 
that incorporates safingol and C2-ceramide for the treatment of AML, with the 
specific objectives for the thesis listed as follows: 
 
1)  To establish a validated analytical method for simultaneous 
determination of safingol and C2-ceramide in murine plasma. This is 
described in section 4.1, where optimized chromatography conditions and 
mass spectrometry parameters for simultaneous determination of the two 
lipids in murine plasma using liquid chromatography tandem mass 
spectrometry (LC/MS/MS) were examined, and the method was subsequently 
validated according to the FDA recommendations on bioanalytical method 
validation. 
 
2) To develop a liposomal formulation of safingol for AML treatment. This 
is described in section 4.2, where a liposomal formulation that incorporates 
safingol was developed to overcome various problems associated with free 
drug of safingol. A series of in vitro and in vivo experiments were conducted 
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to investigate the anti-leukemia activity of liposomal safingol in comparison 
to free safingol. 
 
3) To explore the potential synergistic effect that exists between safingol and 
C2-ceramide. This is described in section 4.3, where C.I. values of 
safingol/C2-ceramide combination were evaluated at different molar ratios in 
AML cell lines to identify the synergistic molar ratio, and a microarray 
approach was used to identify potential molecular targets underlying the 
synergistic anti-leukemic activity of the safingol and C2-ceramide 
combination. 
 
4) To develop a liposome formulation that incorporates safingol and C2-
ceramide at the synergistic molar ratio. This is described in section 4.4, 
where the anti-leukemia activity of a liposomal formulation of bioactive lipid 
combination of safingol and C2-ceramide at the synergistic molar ratio was 
evaluated in AML cell lines, primary AML cells and human AML xenograft 
mouse model. A liposomal formulation of C2-ceramide was developed 
simultaneously to facilitate the comparison of anti-leukemia activity between 
liposomal safingol and liposomal safingol/C2-ceramide combination. 
 
In Chapter 5, several important findings of this research project from the 
formulation and clinical perspectives will be discussed, and the areas of particular 
interest for future investigations will also be highlighted. 
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Chapter 3. Materials and methods 
 
3.1. Lipids, drugs and reagents  
All lipids which include safingol, C2-, C4-, C16-ceramide and DSPC were 
obtained from Avanti Polar Lipids (Alabaster, AL, USA). Safingol and C2-
Ceramide were dissolved in ethanol. Stock solutions of 5x103µM were stored at   
-20°C and freshly diluted with medium to the appropriate concentrations before 
use in experiments. All other chemicals used in the study were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.  
 
3.2. Cell cultures  
Five human AML cell lines representing different subtypes, including KG-1 
(M1), HL-60 (M2), U937 (M5), MV4-11 (M5) and HEL (M6), as well as K-562, 
a cell line of blast crisis of chronic myeloid leukemia (BC-CML), were 
purchased from American Type Culture Collection (Manassas, USA).  Cell line 
NB4 (M3) was acquired from German Collection of Microorganisms and Cell 
Cultures. Stock cultures of the cell lines were maintained in 75-cm2 tissue culture 
flasks (Iwaki, Japan). The cell lines were cultured in Roswell Park Memorial 
Institute Medium 1640 supplemented with 10% v/v fetal bovine serum (FBS; 
HyClone Laboratories, Logan, UT, USA), 0.3 g/L L-glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin. The cell lines were maintained in a 
humidified, 5% CO2 incubator at 37°C and sub-cultured every 2-3 days. All 
experiments were performed using cells in exponential growth phase from 
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passage 5 to 20 post-thawing from frozen stock. Patient AML cell samples were 
provided by Leukemia Tissue Bank, Cancer Science Institute of Singapore. The 
primary leukemia cells were cultured in Iscove’s Modified Dulbecco’s Medium 
supplemented with 20% v/v FBS, 0.3 g/L L-glutamine, 100 ng/mL stem cell 
factor, 50 ng/mL FLT3-ligand, 20 ng/mL interleukin-3, 20 ng/mL 
thrombopoietin, 20 ng/mL granulocyte-macrophage colony- stimulating factor, 
100 U/mL penicillin and 100 µg/mL streptomycin. The collection and the use of 
the patient samples were approved by the Institutional Review Board of National 
University of Singapore. 
 
3.3. Liposome Preparation  
All liposome formulations were prepared by extrusion as described by Hope et al. 
[156]. Individual lipids were weighed and dissolved in chloroform. The dissolved 
lipids were mixed thoroughly to ensure even lipid distribution in the solvent. The 
solvent was removed by evaporation under a gentle stream of nitrogen gas until 
the mixture had a slurry-like consistency. Next, the lipid films were placed under 
high vacuum for a minimum of 3 h to remove residual solvent. Subsequently, the 
lipid films were rehydrated in HEPES buffered saline (HBS, pH 7.5) or 0.3 M 
citric buffer (pH 4.0) at 65°C with vigorous vortexing. The newly formed 
multilamellar vesicles were passed 10 times through an extruder apparatus 
(Northern Lipids Inc., Vancouver, Canada) containing stacked 80- and 100-nm 
polycarbonate filters.  Drugs incorporated in liposomes were separated from the 
unincorporated drugs by centrifuging at 680 × g for 3 min, using 1-mL Sephadex 
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G-50 spin column pre-equilibrated with HBS (pH 7.5). The eluted liposomes were 
collected and analyzed for drug and lipid content to derive the drug-to-lipid (D/L) 
molar ratio. The mean diameter, size distribution and zeta potential of each 
liposome preparation was determined by Zetasizer Nano ZS90 (Malvern 
Instruments GmbH, Herrenberg, Germany).  The liposome samples were 
dispersed in milli-Q water, and measurements were made at 25°C in triplicates 
unless otherwise stated. All liposome samples were stored at 4°C for future 
studies. 
 
3.4. Analysis of drug content in liposomes 
To determine the amount of drugs incorporated in liposomes, drugs were released 
after lysing the liposomes with absolute alcohol. A known volume of internal 
standard (IS) was added to each sample to a final amount of 1 nmol. The drug 
contents in the liposomes were then analyzed using a LC/MS/MS method. The 
method used were similar to the LC/MS/MS method described in section 3.6 
except C16-ceramide was used as the IS and an isocratic elution with 99% 
methanol and 1% 5 mM ammonium formate (pH 4.0) was used.  The run time of 
this method was 5 minutes. 
 
3.5. Phosphate assay 
The lipid concentration in liposomes was determined by phosphate assay. Briefly, 
standards and the liposome samples were heated at 190ºC for 1 h with 700 uL of 
perchloric acid. After  cooling  to  room  temperature,  700 μL  of  fiske  solution  
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and 7 mL  of  ammonium molybdate were added and  further heated  for 20 
minutes at 100ºC. Absorbance was measured at a wavelength of 830nm. Lipid 
concentration was calculated from the phosphate standard curve. 
 
3.6. Quantification of safingol and C2-ceramide by LC/MS/MS  
3.6.1. Preparation of stock solutions, calibration standards and quality 
control standards 
Stock solutions of safingol, C2-ceramide and C4-ceramide (IS) were prepared by 
dissolving the accurate amount of drugs in methanol to a final concentration of 
5mM and stored at -20°C. These solutions were further diluted in methanol to 
obtain working standard solutions at several concentrations. Six calibration 
standards (0.01, 0.05, 0.25, 0.5, 0.75 and 1 µM) were prepared by adding known 
amount of each compound to 20 µL murine plasma. Similarly, four quality 
control (QC) samples at 0.01, 0.1, 0.5 and 0.9 µM were prepared. The calibration 
standards and QC samples were analyzed according to the procedures described 
in section 3.6.2. 
 
3.6.2. Lipid extraction and sample preparation 
Thirty microliter of C4-ceramide (IS) was added to each plasma sample (20 µL) 
to a final amount of 1 nmol. 2mL of methanol: chloroform (1:1 v/v) mixture was 
added to each sample. The mixture was vortex-mixed for 30 seconds and 
sonicated for 2 minutes. After sonication, the mixture was centrifuged at 2000 g 
for 10 minutes. The supernatant was transferred into a clean Eppendorf tube and 
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then dried under a gentle flow of nitrogen gas (TurboVap LV, Caliper Life 
Science, Hopkinton, MA, USA). Finally, the residue was reconstituted with 1 mL 
of the mobile phase for LC/MS/MS analysis. 
 
3.6.3. LC/MS/MS Instrumentation 
LC/MS/MS method development and validation was performed using an Agilent 
1100 HPLC system (Agilent Technologies, Palo Alto, CA, USA) interfaced with 
a triple quadrupole mass spectrometer (API3200, Applied Biosystems, Foster City, 
CA, USA). MS data acquisition and processing were performed using the Analyst 
Software v 1.4.2 (Applied Biosystems, Foster City, CA, USA). All experiments 
were performed using electrospray positive ionization mode (ESI +ve).  
 
3.6.4. MS optimization 
Safingol, C2-ceramide and IS were infused separately at a flow rate of 10 µL/min 
using a built-in microsyringe pump for the optimization of the compound-
dependent MS parameters, including collision energy (CE), collision cell exit 
potential (CXP), declustering potential (DP) and entrance potential (EP). The 
source-dependent MS parameters (temperature (TEM), nebulizer gas 1 (GS1), 
nebulizer gas 2 (GS2), ionspray voltage (ISV) and curtain gas (CUR)) were also 
optimized. The optimized compound and source dependent parameters were used 
for subsequent experiments. Multiple reaction monitoring (MRM) detection was 
employed in all experiments. The analytical column used was an XBridge C18 
Column (3.5 µm, 2.1 x 100 mm, Waters, MA, USA) maintained at 60 ± 1 °C. The 
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HPLC mobile phases consisted of 5 mM ammonium formate, pH 4.0 (A) and 
methanol (B). A gradient elution for HPLC separation at a flow rate of           
0.350 mL/min was used. First, pre-equilibration times of 2 minutes with 25% 
solvent A was carried out, followed by 1% solvent A (0-3 min) and finally back to 
25% solvent A (3-5 min).  
 
3.6.5. Assay validation  
The validation was done according to the FDA recommendations on bioanalytical 
method validation. For a typical validation batch, the sample sequence starts from 
one blank sample, one zero sample, the first calibration standard set, five lower 
limit of quantification (LLOQ) quality control, five Low QC, five Mid QC, five 
High QC, the second matrix sample, the second zero sample and the second set of 
calibration standards. Signal-to-noise ratios of 3 and 10 were defined as the limit 
of detection (LOD) and the LLOQ, respectively. The calibration curves for 
Safingol and C2-ceramide were generated by plotting the peak area ratio of 
analyte/IS against the nominal concentration of the calibration standard samples, 
and linearity was assessed by linear least square regression. The recovery 
experiments were performed in triplicates by comparing the peak area ratios 
obtained from the extracted samples at four concentrations (LLOQ, low QC, mid 
QC and high QC samples) with plasma-free samples containing the same 
concentrations of analytes. The stability of the drugs in plasma was studied with 




3.7. Cell viability assay 
Viability of the cancer cells following drug treatment was determined using the 
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay.  In brief, cells were plated at 250,000 cells per well in 96-well plates and 
treated with drugs ± inhibitors. The plates were then incubated for specified 
period at 37°C.  At the end of the incubation, 50 μL MTT (1 mg/ml in media) was 
added to cells and incubated for 4 h.  Subsequently, the MTT-containing medium 
was removed, and the purple formazan precipitate was solubilized in DMSO. 
Absorbance (λ= 570 nm) was measured in a microtiter plate reader (Tecan, 
Infinite M2000). All assays were done at least three times unless otherwise stated. 
Cancer cell viability was calculated based on the absorbance readings using the 
following equation:  
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =     Abstest – Absblank  Absvehicle control – Absblank   × 100%, 
 where Abstest, Absblank, Absvehicle control represent the absorbance readings from the 
drug-treated wells, the medium only wells and the vehicle control wells, 
respectively.  The potency of the drugs was reflected by their median dose (Dm) 
values which were calculated using CalcuSyn software (Biosoft, Cambridge, UK). 
With respect to drug combination experiments, results obtained from the MTT 
assay were used to compute the C.I. values using CalcuSyn software. 
 
3.8. Flow cytometry with Annexin V-FITC/7AAD  
In brief, 1.0 ×106 cells/mL of U937 and NB4 cells were cultured and treated with 
drugs ± inhibitors. Subsequently, cells were harvested, washed with ice-cold 
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phosphate-buffered saline (PBS) and stained with Annexin V-FITC/ 7-AAD kit 
(Beckman Coulter, France) for 15 minutes in dark. 450 μL of binding buffer were 
added to terminate the reaction. The samples were kept on ice before subjected to 
flow cytometric analysis. Stained samples were analyzed on the Dako flow 
cytometer model CyAn™ ADP, and 10,000 events were collected.  Data were 
plotted with Summit V4.3 Build 2445 software. 
 
3.9. Cell cycle analysis 
Briefly, 1.0 ×106 cells/mL of U937 and NB4 cells were cultured and treated with 
drugs. At the end of the incubation period at 37ºC, 1.0 ×106 cells were harvested, 
fixed with ice-cold 70% v/v ethanol, and stored overnight at −20°C, followed by 
staining with PI staining buffer (1 mg/mL RNase A, 0.1% v/v Triton X-100,      
50 μg/mL PI in PBS) at 37°C for 15 minutes. Stained samples were analyzed by 
flow cytometric analysis using the Dako flow cytometer model CyAn™ ADP, 
and 15,000 events were collected.  Data were plotted with Summit V4.3 Build 
2445 software.   
 
3.10. Cellular uptake of liposomes  
U937 cells were seeded at 1×106 cells/well and treated with 20 µM of liposomal 
formulations 4 and 24 h at 37°C. The liposomes were labeled with 0.5 mol% DiI 
(1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate), as a non-
diffusible liposome dye [152, 157, 158] for tracking liposomes. At the end of 
incubation, cells were harvested and washed twice with PBS. Images of the cells 
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were captured using Olympus FluoView FV1000 confocal laser scanning 
microscope with magnification of 60× objective. 3D images were generated using 
Z stacks of 0.78 µm step size and processed using Imaris 7.2.3 software (Bitplane, 
Zurich, Switzerland). 
 
3.11. Ion exchange chromatography 
 The elution profile of liposome prepared with or without pH gradient was studied 
using a modified method as described by Hope et al. [159]. Freshly prepared 
liposome samples were passed down a Sephadex G-50 column equilibrated with 
10 mM HEPES (pH 7.0) to obtain liposome samples in low ionic strength buffer. 
One milliliter of the sample was added to a CM-Sepharose CL-6B column 
equilibrated with 10 mM HEPES (pH 7.0) with the flow rate adjusted to              
1-2 mL/min. Fractions of 1 mL each was collected. The column was washed with 
0.5 M NaCl, 10 mM HEPES at pH 8.5 to elute any liposome bound to the column. 
Fractions were analyzed using UV-spectrophotometry at 280 nm (UV-1601, 
Shimadzu). 
 
3.12. In vitro hemolytic assay  
The assay was performed according to the modified method by Kedderis et al. 
[160]. Whole rat blood was collected and washed with ice-cold PBS.  Red blood 
cells (4% v/v) were incubated with free drugs or liposomal formulations at 37°C 
for 20 h. After incubation, samples were centrifuged at 2,000 rpm for 5 minutes at 
4°C. Absorbance was measured at 550 nm. Positive control used was sterile water, 
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while negative controls were PBS, HBS or empty liposome. Three different 
batches of liposome formulations were used and all samples were run in 
duplicates.  
 
3.13. In vitro drug release study  
Freshly prepared liposome samples were mixed with FBS at 1:1 v/v and incubated 
at 37ºC over 48 h. Subsequently, 100-μL aliquots of the mixture were removed at 
various time points, and passed down 1-mL Sephadex G-50 spin columns to 
remove released drug.  Lipids were extracted according to modified method of 
Groener et al. [161]. One nmol C4-ceramide was added to the samples as the IS. 
Lipids were extracted with 2 mL chloroform/methanol (1:1, v/v), followed by 
sonication for 15 minutes and incubation at 37ºC for 1 h. Subsequently, 1 mL of 
chloroform and 0.75 mL of milli-Q water was added to the extract to obtain phase 
separation, and the lower chloroform layer was then removed. The upper phase 
was washed once with 1 mL chloroform, and the combined chloroform layers 
were thoroughly evaporated to dryness and reconstituted in 1 mL of 3:2 v/v 
methanol/ 5mM ammonium formate (pH 4.0). The samples were then analyzed 
for drug and lipid content by LC/MS/MS (Section 3.6) and phosphate assay 
(Section 3.5), respectively. 
 
3.14. Plasma elimination study  
All animal studies were completed using protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of National University of Singapore. 
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Free safingol was freshly prepared by dissolving the drug in normal saline 
containing an equimolar amount of lactic acid with pH adjusted to a final value of 
4.4, according to the previously published method by Kedderis et al. [160], which 
was used in the preclinical studies in dogs and rats.  Free safingol, liposomal 
safingol and liposomal C2-ceramide were administrated at 40 mg/kg of the drug 
intravenously into the lateral tail vein of female Balb/c mice (n=3 per time point). 
Similarly, liposome that incorporates safingol and C2-ceramide at 1:1 molar ratio 
was administered at the equivalent of 26.7mg/kg safingol intravenously. At 
various time points after drug administration (0.25, 0.5, 1, 2, 4 & 8 h for free drug; 
0.25, 0.5, 1, 4, 8 & 24 h for liposomal formulations), the animals were euthanized 
by CO2 asphyxiation.  Blood samples were collected by cardiac puncture and 
centrifuged to obtain the plasma which would be stored at −70ºC before analysis 
of drug concentrations by LC/MS/MS as described in section 3.6. The data were 
analyzed using non-compartmental analysis with the software WinNonlin 
Professional (version 5.0.1, Pharsight Corporation, Mountainview, CA) to 
estimate the pharmacokinetic parameters. 
 
3.15. SCID mouse xenograft model of acute myeloid leukemia 
 CB17/Icr-Prkdcscid/IcrCrl (SCID) mice (15-25g) were purchased from Charles 
River Laboratories (Wilmington, MA, USA).  Mice were injected 
intraperitoneally with 100 mg/kg cyclophosphamide (Baxter-Oncology, Deerfield, 
IL, USA) and then inoculated intravenously with 5×106 U937 cells four days after 
preconditioning.  Drug treatments were given to the U937-inoculated SCID 
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intravenously through the lateral tail vein on day 1, 4, 8, 11, 15 and 18 after cell 
inoculation. Each dose of free safingol, liposomal safingol and liposomal C2-
ceramide contained 40 mg/kg of the drug, while liposomal safingol/C2-ceramide 
at 1:1 molar ratio containing 26.7mg/kg of safingol and C2-ceramide each was 
administered. Saline was injected similarly to the vehicle control group.  All 
formulations were freshly prepared. General condition, body weight, neurological 
symptoms and survival of the mice were monitored daily. Mice were euthanized 
if they developed any of the following symptoms: hindlimb paralysis, weight 
loss >20%, scruffy coat, hunched appearance, and moribund state, and death was 
defined as the day following euthanization.  
 
3.16. Staining with modified Wright-Giemsa  
BM samples from the mouse femoral bones prepared by paint-brush technique 
and PB drawn by cardiac puncture were smeared onto standard glass microscope 
slides. Samples were stained with Diff-Quick (modified Wright-Giemsa) stain 
(Baxter Healthcare, Miami, FL). All the slides were evaluated by a board-certified 
hematopathologist who was blinded with respect to treatment condition. All 
photographs were taken with a DP20 Olympus camera (Olympus, Tokyo, Japan) 
using an Olympus BX41 microscope (Olympus) at an original magnification of 
400× unless otherwise stated.  Images were acquired using DP Controller 2002 
(Olympus) and processed using Adobe Photoshop version 5.5 (Adobe Systems, 
San Jose, CA, USA). 
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3.17. Hematoxylin and eosin staining of tissues  
Liver, spleen, sternum and kidney were excised from all six mice in each group. 
The tissues were fixed in 10% buffered formalin, paraffin embedded, and 
subsequently sectioned at 4µm for hematoxylin and eosin (H&E) staining. Tissues 
from six mice per group were stained and evaluated by an ACVP board-certified 
veterinary pathologist. All images were captured using a Leica DM2000 
microscope at an original magnification of 200×.   
 
3.18. White blood cell count   
Venous blood was obtained from mice by cardiac puncture and analyzed using 
Cell-Dyn 3700 hematology analyzer (Abbott Diagnostics, Abbott Park, IL, USA). 
Internal validation was done according to the manufacturer’s instruction. The data 
were expressed as fold change normalized to untreated SCID mice.  
 
3.19. Affymetrix microarray analysis  
The treatment groups for microarray study were ethanol (vehicle control), 
safingol, C2-ceramide and safingol/C2-ceramide combination at 1:1 molar ratio. 
The drugs used in this study were delivered as free drugs in ethanol. U937 cells 
were treated with 10 µM for 12 h and 24 h, while NB4 cells were treated similarly 
for 6 h and 12 h. Cells were then harvested and total RNA was extracted using the 
RNeasy Plus Mini Kit, according to the manufacturer’s instruction (Qiagen, 
Valencia, USA). RNA quantity, quality, and purity were assessed with the use of 
the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent 
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Technologies). Gene expression profiling was performed using Affymetric 
Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) according to the 
manufacturer's protocol. Biological duplicates were performed for each sample. 
Genes with >1.6 fold differences in gene expression between treatment and 
control were identified. The analysis was done separately for the U937 and NB4 
cell lines. These gene lists were then analyzed using Venn diagram to identify 
genes that are uniquely differentially expressed in the safingol and C2-ceramide 
combination in both cell lines. Also, the difference in gene expression profile 
between combination therapy and control was analyzed using gene-set enrichment 
analysis (GSEA). A list of common enriched gene sets in both cell lines were 
generated using a false discovery rate (FDR) of <0.05 and p<0.01. 
 
3.20. Western blotting 
U937 and NB4 cells were treated in the same way as cells in the microarray study. 
After drug treatment, cells were washed with ice-cold PBS and lysed in ice-cold 
cell lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% w/v NP-
40, 20 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 
vanadate, 10% v/v glycerol and 1X protease inhibitor cocktail). Protein 
concentration was determined using the Bio-rad Protein Assay Kit (Biorad 
Laboratories, Hercules, CA).  Proteins were separated by electrophoresis carried 
out on 1.5-mm thick, 7.5% to 12% sodium dodecyl sulfate-polyacrylamide gels 
using Biorad’s Powerpac™ HC Apparatus (Bio-Rad Laboratories, Singapore) and 
electroblotted onto nitrocellulose membranes in ice-cold transfer buffer (39 mM 
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glycine, 48 mM Tris base, 20% v/v methanol). The membranes were subsequently 
blocked with 5% w/v bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, 
USA) in Tris-buffered saline with 0.1% v/v Tween 20 (TBS/T) for 2 h.  The 
membranes were then probed with primary antibodies overnight at 4°C. Primary 
mice monoclonal PRMT5, Cdc25A, MYC, p53 antibodies, and rabbit polyclonal 
MYCBP were purchased from Santa Cruz Biotechnology, Inc (California, USA) 
and diluted with TBS-Tween (TBS/T) containing 5% w/v BSA. Membranes were 
probed with horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-
mice antibody (Pierce Biotechnology, Rockford, IL, USA) for another hour, 
followed by detection with chemi-luminescence Supersignal® West Dura 
Extended Duration Substrate (Pierce Biotechnology, Rockford, IL, USA).  β-actin 
was included as the loading control.  
 
3.21. Statistical analysis  
All data values were reported as mean ± standard error of the mean (SEM). 
Statistical differences were determined using the Student t-test or one-way 
analysis of variance (ANOVA) with Dunnett’s test used for post-hoc multiple 
comparisons. Survival curves were plotted according to the Kaplan-Meier method, 
and the log-rank test was used to determine significant differences among groups. 
P values of < 0.05 were considered to be statistically significant.  
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Chapter 4. Results and discussion 
 
4.1. Simultaneous determination of safingol and C2-ceramide using 
LC/MS/MS  
4.1.1. Section overview 
 Safingol and C2-ceramide are promising bioactive lipids with activity 
against leukemia, and combining them may further improve therapeutic activity. 
Since the concentration ratio of the individual drugs has great impact on the 
response to a combination therapy, an accurate, precise and sensitive analytical 
method is therefore needed to determine the drug concentrations in the in vitro 
release study and pharmacokinetics study. Conventional analytical methods such 
as ultraviolet–visible spectroscopy are not amenable to these drugs as they lack 
chromophores for UV detection. There are several analytical methods for 
identification and quantification of sphingolipids reported in the literature. Some 
prominent examples include thin layer chromatography, high performance liquid 
chromatography and enzyme based assays [162-166]. Plasma concentration of 
safingol has been measured using LC with fluorescence detection following 
chemical derivatization using O-phthalaldehyde (OPA) or naphthalene-2,3-
dicarboxyaldehyde [167]. Similar fluorescence-based analytical methods to 
quantify ceramides have also been described in the literature [168]. These 
methods are tedious and require long assay time. Also, the derivatives produced 
generally have low stability that necessitates analysis immediately post-
derivatization [169]. An E. coli DAG assay has been used extensively for 
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ceramide quantification[170].  This method is less reliable and C2-ceramide is a 
poor substrate of the DAG kinase [169, 171]. The advent of liquid 
chromatography tandem mass spectrometry (LC/MS/MS) method in recent years 
has brought about a sensitive and convenient way to identify and quantify 
sphingolipids. However, no published method is available to determine safingol 
and C2-ceramide levels simultaneously. In this section, an accurate, precise and 
sensitive method for simultaneous identification and quantification of Safingol 
and C2-ceramide in murine plasma by LC/MS/MS was developed. 
 
4.1.2. Section results  
4.1.2.1. Ionization and mass spectrometric characteristics 
The optimized MS parameters were summarized in Table 8. Sphingolipids 
have similar molecular structures with differences in the sphingosine backbone 
and headgroup. These differences provide distinct chromatographic and mass 
spectral characteristics of the analytes. All analytes in this study were analyzed by 
MS in the positive ion mode and showed a protonated molecular ion in 
electrospray ionization.  
The fragment ions selected for Multiple Reaction Monitoring (MRM) 
analysis are the major fragment ions with the highest abundance for each 
sphingolipid. Safingol, a sphinganine produced a product ion at m/z 284 by 
elimination of one water molecule, as shown in Figure 7A. On the other hand, 
both C2-ceramide and C4-ceramide (IS) produced a common product ion at m/z 
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264 by elimination of fatty acid and two hydroxyl groups as shown in Figure 7B 
and 7C, respectively.  
 
Table 8. Optimized MS parameters for the determination of safingol, C2-
Ceramide and C4-Ceramidea. 
a Collision energy (CE); collision cell entrance potential (CEP); collision cell exit 
potential (CXP); declustering potential (DP); entrance potential (EP); nebulizer 
gas 1 (GS1) and nebulizer gas 2 (GS2). 
 
 
Source-dependent parameter  Common  
Curtain gas, psi  15  
Collision gas  Medium  
Ionspray voltage, V  5000  
Temperature, °C  450  
GS 1, psi  40  
GS 2, psi  45  
Interface heater  On  
Compound-dependent parameter Safingol C2-ceramide C4-ceramide 
DP , V 56.0 41.0 31.0 
EP, V 4.5.0 4.0 4.0 
CEP, V 16.0 18.0 26.0 
CE, V 19.0 25.0 25.0 











Figure 7. Product ion mass spectra of (A) safingol, (B) C2-ceramide and (C) C4-
ceramide. 
 
4.1.2.2. Selection of Chromatographic Condition 
Selection of methanol and ammonium formate (5 mM; pH 4) as solvents 
for the mobile phase was based on the information available in the literature [70]. 
Isocratic elution was attempted initially using a mobile phase of               
methanol: ammonium formate (75/25, v/v) at a flow rate of 0.35 mL/min and 
60ºC. However, under such conditions, all analytes had broad peaks. Therefore, 
gradient elution was adopted. First, pre-equilibration time of 2 minutes with 25% 
of solvent A (5 mM ammonium formulate; pH 4) was carried out, followed by 1% 
solvent A (0-3 min) and finally back to 25% solvent A (3-5 min) at a flow rate of 
0.35 mL/min and 60ºC throughout the run. To maximize assay sensitivity, an 
injection volume of 100 μL was used and all analytes exhibit acceptable peak 













Figure 8. Representative chromatograms of (A) blank murine plasma (B) murine 
plasma spiked with C4-ceramide (C) murine plasma spiked with known amounts 
of analytes and C4-ceramide. (1) safingol, (2) C2-ceramide and (3) C4-ceramide. 
 
4.1.2.3. Method validation 
4.1.2.3.1. Specificity  
Representative chromatograms of extracted blank mouse plasma and 
extracted mouse plasma spiked with safingol, C2-ceramide and/or C4-ceramide 
(IS) are shown in Fig. 8.  No notable interference for the two analytes and the IS 
were observed in the chromatograms obtained from the extracted plasma samples. 
The retention times for safingol, C2-ceramide and C4-ceramide were found to be 









The LLOQ for safingol was 0.01 µM, with accuracy of 105.8% and C.V. 
of 5.2, and the LLOQ for C2-ceramide was 0.01 µM, with accuracy of 96.8% and 
C.V. of 11.5. The LOD were for safingol and C2-ceramide were 0.003 µM.   
 
4.1.2.3.3. Linearity 
The linearity of the assay procedure was determined by assessing the fit of 
the regression line using the method of 1/x2 weighted least square analysis. The 
standard calibration curves were linear over the range of 0.01µM to 1µM for both 
drugs with the equations of y = 0.548 x + 0.00321 (r2 = 0.996) and                        
y = 0.893 x + 0.0049 (r2 = 0.994) for safingol and C2-ceramide, respectively. 
 
4.1.2.3.4. Absolute recovery 
Protein precipitation technique was found to be efficient, and consistent 
recoveries with acceptable C.V. for all analytes were obtained (Table 9).  The 
absolute recovery of safingol at 0.01 µM, 0.1 µM, 0.5 µM and 0.9 µM ranged 
from 93.6% to 104.3% while the absolute recoveries of C2-ceramide were from 
87.1% to 111.5% (Table 9). The high recovery obtained is important to achieve 




Table 9. Absolute recovery of QC samples of safingol and C2-ceramide. 
 
4.1.2.3.5. Accuracy and precision 
The results for accuracy and precision validation of our method are shown 
in Table 10. The intraday C.V. were less than 12.5%, and the intraday accuracies 
were between 93.8 and 108.9%. The inter-day validation also showed good 
accuracy and precision, with C.V. less than 11.5% and accuracy between 91.3 and 
106.3%. 
 
Table 10. Accuracy and precision of QC samples of safingol and C2-ceramide. 
n=5 
 
Analyte Nominal concentration (µM) 
Absolute recovery 
(%) C.V. (%) 
safingol 
0.01 100.1 10.9 
0.1 98.1 11.0 
0.5 104.3 2.6 
0.9 93.6 14.6 
C2-ceramide 
0.01 107.3 7.8 
0.1 111.5 10.1 
0.5 105.0 1.6 
0.9 87.1 11.1 







(%) C.V. (%) 
Accuracy 
(%) C.V. (%) 
safingol 
0.01 108.5 6.5 105.8 5.2 
0.1 97.0 5.5 103.3 5.6 
0.5 99.9 9.3 99.8 7.3 
0.9 93.8 9.8 100.1 6.9 
C2-
ceramide 
0.01 95.7 12.5 96.8 11.5 
0.1 108.9 3.8 106.3 6.3 
0.5 99.6 6.3 97.9 7.3 
0.9 94.9 9.6 91.3 7.0 
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4.1.2.3.6 Stability in plasma samples 
The stability of safingol and C2-ceramide in plasma samples have been 
described previously [172, 173]. Stability of the analytes in plasma was studied 
after storage at -70ºC for 1 year, and the stability of all analytes were found to be 
satisfactory and the reduction in initial drug concentration was <15% (Table 11). 
 
Table 11. Stability of safingol and C2-ceramide after storage at -70 ºC for 1 year. 
n=3 
 
4.1.3. Section discussion 
 
Till date, there is no analytical method available for simultaneous 
quantitative determination of safingol and C2-ceramide in biological samples. 
Hence, it is necessary to develop a validated method to quantify these two drugs 
simultaneously in murine plasma samples. In addition, method validation is 
carried out according to the FDA recommendations on bioanalytical method 
validation in order to ensure reliability and reproducibility of the analytical 
method.  
Our method has the advantage of much shorter sample preparation time 
and higher sensitivity as compared to the various derivatization methods [168, 
174-177]. More importantly, none of the previous methods were able to 
Analyte Concentration (µM) Percentage remaining (%) C.V. (%) 
safingol 
0.1 91.9 1.5 
0.5 98.6 13.1 
0.9 104.3 12.1 
C2-ceramide 
0.1 89.0 11.5 
0.5 102.2 3.6 
0.9 99.2 4.7 
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simultaneously quantify safingol and C2-ceramide. Also, it is important to realize 
that derivatization methods may not be suitable for the simultaneous analysis of 
safingol and C2-ceramide. C2-ceramide needs to be deacylated to form 
sphingosine in order to expose the primary amine group for fluorescence 
derivatization. This method would result in the formation of two derivatized 
entities that are very similar in structure, differing only by two hydrogen atoms 
(safingol and sphingosine). Such similarity would pose a challenge in 
chromatographic separation. 
In summary, an accurate, precise and sensitive method suitable for 
simultaneous analysis of Safingol and C2-ceramide using LC/MS/MS was 
developed. The method also demonstrated good linearity and extraction 
efficiency. This validated analytical method will be used in the preclinical 




4.2. Development of a novel liposomal formulation of safingol in the 
treatment of acute myeloid leukemia1 
4.2.1. Section overview 
This section addresses the approach to develop a liposome formulation of 
safingol in the treatment of acute myeloid leukemia. Owing to its poor solubility, 
safingol is administered as an oil-based emulsion; however, this formulation 
suffers from severe hemolysis as the dose-limiting toxicity in pre-clinical animal 
studies [160]. Hence, a suitable drug delivery system is necessary to overcome the 
problems associated with safingol. Liposome is one of the most advanced drug 
delivery system for anti-cancer drugs, with a number of clinically approved 
liposome drug products in the market [178], and it has the advantages of being 
non-toxic, non-immunogenic and biodegradable in general. The pharmacokinetics 
of the liposome-encapsulated drug will be modified such that distribution to 
normal tissues is reduced, thereby lowering drug toxicity.  Furthermore, the drug 
can be protected, to varying extent, from immediate dilution, degradation or 
inactivation after administration into the bloodstream.  Of note, liposome delivery 
systems have been used to address the issues of poor solubility and hemolytic 
toxicity of various bioactive lipids, including ceramides and ether lipids [179, 
180].  Therefore, it is anticipated that liposome incorporation of safingol would 
yield a viable injectable drug product without the need of toxic vehicle such as 
ethanol or Cremophor-EL, and would substantially reduce the hemolytic toxicity 
of safingol.  The present study is the first to describe a rationally designed 
                                                     
1 Data except Figure 12B, Figure 13 and Table 12 have been published in Tan et al., In vivo 
efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia, 
Journal of Controlled Release, 160 (2012) 290-298. 
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liposome formulation of safingol and demonstrate the anti-leukemic potential of 
liposomal safingol using a panel of human AML cell lines and patient cell 
samples as well as a murine xenograft model of human U937 monocytic leukemia.  
 
4.2.2. Section results 
4.2.2.1. Liposome formulation development for safingol 
Since safingol is a hydrophobic drug which is insoluble in water, it was 
first mixed with DSPC and CHOL during the process of lipid film formation.  By 
this method, safingol will be entrapped in the lipid bilayer when liposomes are 
formed.  The citrate-based pH gradient was generated across the liposomal lipid 
bilayer, as it is a commonly used loading technique to improve the retention of 
lipophilic, protonable drug compounds [181]. The incorporation efficiency of 
safingol into the DPSC/CHOL liposomes at 7.5 mol% in the presence of pH 
gradient was 98.6 ± 7.0%. The cytotoxicity of liposomal safingol was investigated 
in NB4 and U937 cells.  Interestingly, the cytotoxicity of liposomal safingol was 
completely abolished when it was incorporated in the liposomes prepared with pH 
gradient (Figure 9).  In view of the observations, liposomal safingol prepared 
without pH gradient was evaluated for its anti-leukemic activity, and was found to 






Figure 9. Effect of pH gradient on the antileukemic activity of liposomal safingol 
in NB4 and U937 AML cell lines. Cells were treated with liposomal safingol with 
pH gradient ( ♦) or without pH gradient ( ■) for 72 h. Cell viability was assessed 
using MTT assay. Results shown are means ± SEM from three independent 




Based on these observations, it was postulated that the significant 
reduction in anti-leukemic activity might be due to lower cellular uptake of the 
liposomes, which in turn, was influenced by the zeta potential of the liposomes. 
Cellular uptake of liposomal safingol was studied using DiI, an established non-
diffusible marker that was used to track liposomes in vitro and in vivo, as it would 
not diffuse from the liposomes to the cells [152, 157, 158]. From Figure 10, 
increased cellular accumulation could be observed with liposomal safingol 
prepared without pH gradient as a function of time, whereas liposomal safingol 
with pH gradient showed minimal cellular accumulation. The zeta potential of 
non-drug loaded DSPC/CHOL liposomes in the absence and presence of pH 
gradient was -0.63 ± 0.40 mV and -7.64 ± 0.45 mV, respectively.  The zeta 
potential of liposomal safingol in the absence and presence of pH gradient was 
+39.6 ± 2.2 mV and   -6.87 ± 0.96 mV, respectively. These findings were further 
supported by the elution profile of liposomal safingol using cation exchange 
column, where liposomal safingol prepared without pH gradient was retained by 
the column and was not eluted until the column was washed with 0.5 M NaCl, 
while liposomal safingol prepared with pH gradient was eluted in the void volume 
(Figure 11).  This could be due to preferential localization of safingol to the inner 
monolayer of liposome and this effect will be further discussed in section 4.2.3. 
Taken together, our results are supportive of the notion that the anti-
leukemic activity of liposomal safingol was dependent on a positive zeta potential 
which in turn influenced cellular uptake of the liposome formulation.  Therefore, 
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liposomal safingol prepared without pH gradient was used for all subsequent 
experiments. 
 
Figure 10. Cellular accumulation of liposomal safingol with or without pH 
gradient. U937 cells were treated with 20 µM DiI-labeled liposomal safingol for 4 
and 24 h. Representative images from three independent experiments were shown, 
and were taken using Olympus FluoView FV1000 microscope at ×60 objective 
magnifications. The overlay images were merged images of Differential 
Interference Contrast and DiI channels, and the 3D images were processed from 




Figure 11. Elution profile of liposomal safingol. Empty DSPC/CHOL liposomes 
prepared with pH gradient (A) or without pH gradient (B), or liposomal safingol 
prepared with pH gradient (C) or without pH gradient (D) were passed down a 
CM-Sepharose CL-6B column equilibrated with 10 mM HEPES (pH 7.0). 
Fractions of 1 mL were collected and analyzed spectrophotometrically at 280 nm. 
Arrows indicate elution with 0.5 M NaCl, 10 mM HEPES, pH 8.5. Representative 
chromatograms from three independent experiments were shown.  
 
It was of importance to investigate the incorporation efficiency of safingol 
into the liposomal lipid bilayer.  When 5, 7.5 or 10 mol% safingol was used, it 
yielded approximately 100% incorporation efficiency into liposomes without pH 
gradient, and drug content did not change over the working period of 7 days when 
samples were kept at 4°C (Figure 12A and 12B). Liposome containing 7.5 mol% 
safingol was used for all subsequent experiments, as it yielded the highest 
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incorporation efficiency among the three formulations tested. As shown in Figure 
13, the size of liposomal safingol at 7.5mol% was approximately 120 nm as 
reflected by the cryo-TEM images, and there was no significant change in 
liposome size and polydispersity over 7-day storage period at 4ºC (Table 12). 
Figure 12C depicts the release profile of safingol from this liposome system after 
incubation with 50% v/v fetal bovine serum at 37°C. The data were fitted to the 
three most common models of drug release, namely, zero-order, first-order and 
square-root-of-time release, with correlation coefficients of 0.90, 0.84, and 0.96, 
respectively. The square-root-of-time release model gave the best fit, which 
suggested that safingol incorporated in the liposome had to diffuse through the 




Figure 12. Formulation characterization of liposomal safingol. (A) Incorporation 
efficiency of safingol in DSPC/CHOL liposome at 5, 7.5 and 10 mol%. Safingol 
was incorporated into DSPC and CHOL liposomes without pH gradient. Results 
shown are means ± SEM from three independent experiments. Liposome with 7.5 
mol% safingol was used for all subsequent experiments. (B) The drug retained in 
the liposomal safingol stored at 4°C over 7 days. Results shown are means ± SEM 
from three independent experiments. (C) The drug release profile of liposomal 
safingol in the presence of serum at 37°C over 48 h. Results shown are means ± 
SEM from three independent experiments.  
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(A)         (B) 
 
Figure 13. Cryo-Transmission Electron Microscopy images of (A) empty 
DSPC/CHOL liposomes and (B) liposomal safingol. Representative images of 
liposomes from each group were shown. The scale bars represent 200nm. 
 
 
Table 12. Size analysis and polydispersity of liposomal safingol stored at 4°C 
over 7 days. 
 
4.2.2.2. In vitro cytotoxicity of liposomal safingol  
The cytotoxicity of liposomal safingol was investigated using a panel of 
AML cell lines covering most of the French-American-British (FAB) subtypes, 
including KG-1 (M1), HL-60 (M2), NB4 (M3), U937 (M5), MV4-11 (M5) and 




Day 0 Day 1 Day 7 
Size (nm) PDI Size (nm) PDI Size (nm) PDI 
5 124 ± 1 0.06 ± 0.02 122 ± 0.2 0.03 ± 0.01 121 ± 1 0.04 ± 0.01 
7.5 126 ± 3 0.05 ± 0.04 130 ± 1 0.06 ± 0.01 132 ± 6 0.09 ± 0.04 
10 132 ± 9 0.10 ± 0.03 135 ± 6 0.07 ± 0.02 138 ± 2 0.12 ± 0.08 
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(BC-CML). The concentration of safingol tested ranged from 0.625–20 µM with 
an exposure period of 72 h. Inhibitory concentration at 50% effect level (IC50) 
was estimated using the CalcuSyn software. The results showed dose-dependent 
decrease in leukemic cell viability after exposure to liposomal safingol for 72 h, 
with IC50 values ranging from 1.5–13 µM (Table 13 and Suppl. Figure 1).  
Among the various AML subtypes, NB4 (M3) was found to be the most sensitive 
cell line with the lowest IC50 value of 1.5 ± 0.2 µM. More importantly, the IC50 
values of liposomal safingol were of the same order of magnitude as free safingol 
in vitro.  
 
Table 13. IC50 of free and liposomal safingol in various AML cell lines. 
Cell viability was determined using MTT assay and subsequently analyzed by 
CalcuSyn software to estimate IC50 values. Data are mean ± S.E.M obtained from 
three independent experiments. Values are expressed in 2 significant figures. R 




IC50  (µM) 
Free safingol Liposomal safingol 
KG-01 M1 3.1 ± 0.3 (0.98) 7.3 ± 0.4 (0.99) 
HL-60 M2 3.5 ± 0.6  (0.96) 7.5 ± 0.8 (0.92) 
NB4 M3 1.7 ± 0.4 (0.95) 1.5 ± 0.2 (0.96) 
U937 M5 3.4 ± 0.6 (0.95) 10 ± 1.6 (0.97) 
MV-4-11 M5 2.6 ± 0.4 (0.95) 6.1 ± 0.9 (0.99) 
HEL M6 4.8 ± 0.7 (0.98) 10 ± 0.3 (0.99) 
K562 BC-CML 5.7 ± 0.2 (0.90) 13 ± 4.8 (0.98) 
 81 
 
In order to demonstrate the clinical potential of liposomal safingol, 
leukemia cells obtained from AML patients were used for testing. The IC50 values 
for the patient samples were in good agreement with those observed in the 
leukemia cell lines, with IC50 values ranging from 4.3–12 µM (Table 14 and 
Suppl. Figure 2). In addition, viability of U937 leukemic cells was found to be 
83.4 ± 4.9% of untreated control after treated with 50 mM DSPC/CHOL empty 
liposomes for 72 h. This finding indicated that empty, drug-free liposomes 
contributed minimal cytotoxicity even at 50 mM. As free safingol has been shown 
to induce the generation of reactive oxygen species (ROS) that is important to cell 
death [41], the ability of liposomal safingol to induce apoptotic cell death via 
ROS generation was further examined in the presence of ROS scavenger, N-
acetylcysteine (NAC).  Cell viability was significantly higher when liposomal 
safingol-treated leukemic cells were incubated in the presence of NAC (Figure 




Table 14. IC50 of liposomal safingol in primary leukemia cells from AML patients. 
Cell viability was determined using MTT assay and subsequently analyzed by 
CalcuSyn software to estimate IC50 values. Data are mean obtained from one 
independent experiment done in triplicates. Values are expressed in 2 significant 









Karyotype IC50  (µM) 
1 69/F M1 




2 48/M M2 46,XY[18] 7.6 (0.96) 
3 37/M M2 46,XY[20] 4.3 (0.98) 





5 32/M M4 46,XY[20] 9.2 (0.98) 























Figure 14. ROS mediate the apoptotic cell death in liposomal safingol-treated 
AML cell lines. Flow cytometric analysis of NB4 and HL-60 cells after treated 
with 1.25μM and 10μM safingol ± 10 mM NAC for 24 h, respectively. Cells were 
harvested and stained with Annexin V-FITC/7AAD before analyzed by flow 
cytometry. (A) Representative dot plots from three independent experiments were 
shown. (B) Percentage of double negative cells (Annexin V-FITC -ve; 7AAD -ve) 
were shown. Each reported value represents the mean ± SEM from three 






4.2.2.3. Hemolysis induced by free safingol could be significantly reduced 
through liposome incorporation 
As demonstrated in preclinical studies, the dose-limiting toxicity of 
safingol is hemolysis [58, 160].  From Figure 15, a concentration-dependent 
increase in hemolysis could be seen when red blood cells were incubated with 
free safingol.  When safingol was incorporated in liposomes, its hemolytic effect 
could be significantly reduced (p<0.05). 
 
Figure 15. Hemolytic toxicity of safingol was significantly reduced through 
liposome incorporation. Percentage of hemolysis of free safingol ( ♦) was 
compared to liposomal safingol (■) after incubation with 4% red blood cells for 
20 h at 37°C. Positive control used was sterile water while negative control was 
HBS. Ethanol was used as the vehicle control for free safingol. DSPC/CHOL 
empty liposome without safingol was used as the lipid control for liposomal 
safingol. Each reported value represents the mean ± SEM from three independent 
experiments (* p<0.05, compared to free safingol). 
 85 
 
4.2.2.4. Liposome incorporation of safingol increased the systemic drug 
exposure in mice 
Plasma elimination profiles were obtained for free and liposomal safingol 
after an intravenous bolus dose of 40 mg/kg and plasma samples were analyzed 
using the validated LC/MS/MS method developed in section 4.1 (Figure 16). The 
results demonstrated that free safingol was rapidly cleared from the bloodstream, 
whereas the concentration of safingol in liposome form remained detectable 
throughout the 24-h course of study. The data on plasma drug concentrations for 
the two forms of safingol were analyzed by non-compartmental analysis with the 
WinNonlin software to estimate the pharmacokinetic parameters which are 
summarized in Table 15. Through liposome incorporation, the circulation 
longevity of safingol could be substantially extended, as reflected by a 2.1-fold 
increase in the mean residence time (MRT).  More importantly, the systemic drug 
exposure, as reflected by the area under the plasma concentration-time curve 
(AUC), has been increased three orders of magnitude by formulating safingol into 
DSPC/CHOL liposomes, despite a positive zeta potential borne by this liposome 
system. The increase in AUC could be attributed to the significant reduction in 
clearance (CL) and volume of distribution at steady state (Vss) of liposomal 
safingol as compared to free safingol. The changes in the pharmacokinetic 
behavior of liposome-incorporated safingol are in line with other liposomal drug 






Figure 16. Plasma elimination profiles of free ( ♦) and liposomal safingol (■). An 
intravenous bolus injection of free and liposomal safingol was given to Balb/c 
mice at a dose of 40 mg/kg.  Each time point represents the mean plasma drug 



























Table 15.  Pharmacokinetic parameters for free and liposomal safingol in Balb/c 
mice. 
a Non-compartmental analysis was used to estimate the various pharmacokinetic 
parameters.  Four and six time points were used for the estimation of the terminal 
elimination phase for free and liposomal safingol, respectively. In the calculations, 
first order elimination was assumed, and uniform weighting was used. 
bAUClast, area under curve from time of dosing (t = 0 h) up to the last measured 
concentration (t = 8 h for free safingol and 24 h for liposomal safingol);    
AUMClast, area under moment curve from time of dosing (t = 0 h) up to the last 
measured concentration; MRTlast, mean residence time which is calculated based 
on values up to the last measured concentration; CL, total body clearance; Vss, 
volume of distribution at steady state; R2, goodness of fit statistic for the terminal 
elimination phase; Corr (x:y), correlation between time (X) and log concentration 
(Y) for the points used in the estimation of the first order rate constant associated 




Parameter a ,b Free safingol Liposomal safingol Fold change 
AUClast (µM  h) 1.56  × 101 1.76 × 104 ↑ 1128× 
AUMClast (µM  h2) 2.67  × 101 6.47 × 104 ↑ 2423× 
MRTlast (h) 1.72 3.65 ↑ 2.1× 
CL (mL/h) 133 0.150 ↓ 886× 
Vss (mL) 625 0.559 ↓ 1118× 
R2 0.939 0.995 N.A. 
Corr (x:y) -0.969 -0.997 N.A. 
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4.2.2.5. Liposomal safingol significantly improved the survival of U937-
inoculated SCID mice 
A physiologically relevant model of AML was established by intravenous 
inoculation of U937, a human monocytic leukemia cell line which harbors the 
translocation t(10;11)(p13;q14) known to be associated with poor prognosis [183, 
184], into SCID mice to provide suitable conditions for the evaluation of anti-
leukemic effect of free and liposomal safingol.  The U937 xenograft model was 
chosen because of the extreme aggressiveness of U937 cells which mimics the 
aggressive leukemic burden in AML and permits the evaluation of therapeutic 
efficacy in a relatively short period of time. It has been established that this 
xenograft model would infiltrate BM and various organs including meninges 
(leading to neurological symptoms), liver, spleen, lung, and brain [185, 186]. The 
animals were preconditioned with cyclophosphamide before intravenous 
inoculation of U937 cells [185].  The inoculated mice were then randomized into 
the 3 study groups: saline control, free safingol and liposomal safingol, with the 




Figure 17. In vivo efficacy of liposomal safingol in U937-inoculated SCID mice. 
(A) Timeline of U937 xenograft model and treatment schedules. Arrows indicate 
the days for cyclophosphamide preconditioning, cell inoculation and treatment.  
(B) Kaplan-Meier survival curves of the U937-inoculated SCID mice over 60 
days post inoculation. Preconditioned SCID mice were inoculated intravenously 
with 5×106 cells of U937 on day 0. Free safingol (dotted-line) and liposomal 
safingol (dashed-line) was administered intravenously at 40 mg/kg. Mice from the 
control group (continuous-line) were given normal saline in the same way.  (C) 
Evaluation of U937 cell infiltration (arrow) in PB and BM of the SCID mice at 
the end point of the study. PB and BM smears were stained with modified 
Wright-Giemsa. Representative images of PB and BM smears from each group 
were shown. Magnifications were 400× for all the images. 
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The saline control group exhibited a median survival time (MST) of 20 
days (Table 16 and Figure 17B). All of the animals, vehicle control or drug-
treated, developed hindlimb paralysis during the course of the study, a symptom 
that is in line with those described previously [185, 186]. Both free and liposomal 
safingol were effective in eliminating U937 cells in PB and BM, as illustrated by 
the Giemsa-stained PB and BM smears (Figure 17C). From the quantitative WBC 
count (Figure 18), free safingol and liposomal safingol significantly reduced the 
number of leukocytes in PB of treated mice as compared to vehicle control mice. 
 
Table 16. Median survival time, increased median lifespan and percentage of 
weight loss at nadir of U937 human leukemia xenograft model in SCID mice (n = 
6). 
a  MST = Median survival time.  
b  Percent increase in life span (% ILS) = (MST of treatment group – MST of 
saline control) / MST of saline control ×100%. 
c Percentage weight loss at nadir = (Weight at nadir - Initial weight before 
treatment)/ Initial weight before treatment ×100%. 
d   P <0.05, statistically significant difference as compared to the control group. 
e   P<0.05, statistically significant difference as compared to free safingol. 
Treatment group MSTa (days) % ILSb % Weight loss at nadirc 
Saline control 20 N.A. 7.37 ± 1.50 
Free safingol 23d 15 5.27 ± 2.24 




Figure 18. Effect of free safingol and liposomal safingol on the number of 
leukocyte in peripheral blood of mice. Venous blood of mice was obtained by 
cardiac puncture at the end point of the study and the number of leukocyte was 
determined using a hematology analyzer. Each reported value represents the mean 
± SEM obtained from six mice (*p<0.05, compared to saline control). 
 
Leukemic cell burden could be present in other organs such as those of 
neurological infiltration. Indeed, neurological infiltration has been established as 
the euthanization endpoint of U937-inoculated animal efficacy study [185, 186], 
which was also employed in our current study.  Administration of free safingol 
extended the Median survival time (MST) from 20 days to 23 days, with 15% 
increase in lifespan (ILS) of the U937-inoculated mice (p<0.005). Of note, 
liposomal safingol as compared to free safingol was more effective, whereby the 
MST of the U937-inoculated mice was further extended to 31 days to yield 55% 


































comparing liposomal safingol and free safingol).  The statistical significant 
difference in the MST between free and liposomal safingol indicated that 
treatment with liposomal safingol could delay the development of hindlimb 
paralysis due to neurological infiltration as compared to free safingol as well as 
reducing the extent of infiltration to liver, spleen and kidney (Table 17).  These 
findings suggest that liposomal delivery could improve the therapeutic efficacy of 
safingol. Preliminary evaluation of systemic toxicity showed that minimal 
treatment-related toxicity was observed in liver, kidney and spleen at the dose of 
40 mg/kg of free and liposomal safingol, as reflected by minimal cellular 
degeneration in the H&E stained tissue sections read by the veterinary pathologist 
(Figure 19). Of note, only mice treated with liposomal safingol did not experience 
significant weight loss as compared to the control mice (Table 16).  
 
  
Table 17. Leukemic cell infiltration of U937 human leukemia xenograft model in 
SCID miceb. 
Treatment group 
Leukemic cell infiltrationa 
Liver Kidney Spleen 
Saline control 3/6 5/6 5/6 
Free safingol 3/6 3/6 1/6 
Liposomal safingol 2/6 2/6 1/6 
a Number of mice that exhibited U937 cell infiltration as solid masses. 









































































































































































4.2.3. Section discussion 
In search of novel anti-cancer treatments, the sphingolipid pathway has 
received much attention over the last decade.  In addition to their role in 
regulating cell membrane fluidity, sphingolipids have emerged as important 
modulators in intracellular signaling and cellular functions [73]. Safingol, a 
member of the sphingolipid family, has been shown to be efficacious in vitro as a 
single agent against various human leukemia cell lines.  The main challenges to 
translate safingol into clinical use include its low water solubility and hemolytic 
toxicity.  While safingol has been tested in combination with cisplatin in a 
recently completed Phase I clinical trial for advanced solid tumors whereby 
safingol was administered as an oil-based emulsion [51], the formulation still 
showed significant distribution of the drug to red blood cells, suggestive of 
potential hemolysis [187].  As such, we aimed to develop appropriately designed 
liposome delivery system to overcome the aforementioned challenges.  The 
biological performance of liposomal safingol from our in vitro and in vivo 
evaluation will be discussed in light of the formulation design and attributes.  
The pH gradient-based drug loading technique is a well established 
method for the liposome incorporation of lipophilic drug compounds with 
protonable amines [181].  As shown in Figure 4A, safingol which has a weakly 
basic primary amine group in its structure would thus be responsive to pH 
gradient loading so as to promote drug retention.  Of importance, the use of 
citrate-based pH gradient in liposomal safingol completely abolished its cytotoxic 
activity over the range of drug concentrations tested (Figure 9).  This prompted us 
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to further investigate into the charge on the liposomes and cellular accumulation 
that may have influenced the biological activity. A previous study demonstrated 
the localization of stearylamine and sphingosine in the inner monolayer of a 
liposome with an acidic interior [159], whereby the pH gradient across the lipid 
bilayer served as the driving force for the basic sphingolipid to flip from the outer 
to the inner monolayer of the liposome and created asymmetry in bilayer lipid 
distribution.  Safingol, sharing structural similarity with stearylamine and 
sphingosine, is anticipated to flip to the inner monolayer in response to the pH 
gradient, and this has resulted in a change in the zeta potential of the liposomes 
from +39.6 to –6.87 mV. The elution profile of liposomal safingol further 
substantiates this postulation (Figure 11).  
Surface charge of a liposome is an important parameter that will affect its 
interaction with cells [188, 189].  Indeed, the change in zeta potential of the 
liposomes when the pH gradient was applied has resulted in lower cellular 
accumulation of liposomes, which could possibly affect the anti-cancer activity 
due to low intracellular drug accumulation. Taken together, sphingolipids with 
protonable amine group such as safingol may not be amenable to the method of 
pH gradient loading which has significantly affected the anti-leukemic activity, 
and their presence could dramatically change the formulation attributes and 
biological performance of the liposome carrier.    
Despite the fact that positive charge on liposomes promote cellular 
interaction, this attribute could also promote rapid elimination of the liposomes 
from circulation [190]. As evidenced by the pharmacokinetic profile of liposomal 
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safingol, the positive zeta potential of the formulation did not result in rapid 
elimination of the drug from the bloodstream.  In fact, liposomal safingol behaved 
as expected from a liposome formulation in which systemic drug exposure, as 
reflected by the AUC values, has been increased by three orders of magnitude 
through liposome incorporation. Our results have demonstrated that liposome 
incorporation could facilitate the delivery of safingol to achieve therapeutic level 
for its anti-leukemia activity in vivo. Elimination of leukemic cells in peripheral 
blood would be enhanced through the increase in systemic drug exposure, as 
evidenced by the blood smear images in Figure 19.  The increase in systemic drug 
exposure could be attributed to the liposomal lipid composition as well as the 
lipid dose administered.  The use of saturated phospholipid coupled with a high 
CHOL content (40 mol%) in the liposome formulation has been shown to increase 
accumulation of liposomes in the bone marrow [191], which facilitates the 
homing of drug compounds to the site of origin of AML.  At 40 mg/kg safingol, 
the lipid dose given was 1 g/kg, a dose at which saturation of the MPS involved in 
the liposome uptake and removal would occur and increase the plasma 
concentrations of the liposome carrier [192].  The drug-free DSPC/CHOL 
liposomes was found to be minimally cytotoxic at 50 mM in our in vitro MTT 
assay, which is in line with previous observations that this lipid composition was 
not found to exert any significant effect on tumor growth and survival of animals 
[193, 194]. Of note, the LD50 for empty liposomes has been reported to be as high 
as 7.2 g/kg [130, 195]. 
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In addition to increased systemic drug exposure, the hemolytic effect of 
safingol could be significantly reduced through formulating into a liposome 
delivery system (Figure 17).  Many theories have been proposed to describe the 
different mechanisms of hemolysis caused by amphiphilic, surface active drugs 
such as safingol.  It is widely believed that most drugs induce hemolysis via a 
mechanism that is very similar to that described for classical detergents, whereby 
hemolysis occurs as a result of removal of red cell membrane components when 
the drug concentration in the surrounding medium exceeds its critical micellar 
concentration, giving rise to lipid-drug, protein-drug or lipid-protein-drug mixed 
micelles [196].  The data presented in Figure 17 suggest that safingol is stably 
associated with the liposome delivery system, as incubation of liposomal safingol 
caused little or no hemolysis, suggesting a free safingol concentration in the 
incubation medium that is below the critical micellar concentration.   
Collectively, our current study has demonstrated the therapeutic potential 
of liposomal safingol as a single agent for AML through in vitro leukemic cell 
lines, in vivo xenograft model, and human patient samples. It is envisioned that 
liposomal safingol could be used for the co-delivery of drug and gene 
combination therapy, as the liposome formulation bears a positive zeta potential 
to promote cellular and DNA interaction. While the results presented in this 
section seemed promising, further improvement in therapeutic activity could be 
brought about by means of combination therapy. In the next section, the 
development of bioactive lipid combination as the strategy to achieve synergistic 
anti-leukemia activity will be investigated. 
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4.3. Rational combination of safingol and C2-ceramide in the treatment of 
acute myeloid leukemia 
4.3.1. Section overview 
A combination approach of safingol with other conventional 
chemotherapy has been pursued with the aim of reducing resistance and achieving 
better outcomes in cancer patients as discussed in previous sections. This section 
will describe a novel combination of bioactive lipids, namely safingol and C2-
ceramide, for the treatment of AML. The selection of individual agents in the 
combination is based on the potential synergistic effect that exists between the 
agents presumably via different mechanisms of action to target different 
leukemogenic pathways of AML. While the probability of achieving a cure in 
patients treated with drug combination is generally higher, one must consider the 
concentration ratio of the individual drugs at the site of action, which in turn, 
dictates the potential synergistic or antagonistic effects of the drug combination 
[55, 103]. This section aimed to identify a synergistic molar ratio of safingol and 
C2-ceramide combination on a wide range of AML cell lines. In addition, this 
section will also present novel molecular targets underlying the synergistic 
interactions of safingol and C2-ceramide in AML.  
 
4.3.2. Section results  
4.3.2.1. Identification of synergistic ratio of safingol and C2-ceramide  
This section focuses on the strategy to combine safingol and C2-ceramide 
at a synergistic drug ratio to achieve improved anti-leukemic activity. Prior to 
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studying the combination effect, the efficacy of C2-ceramide as single agent was 
first evaluated. Cytotoxicity of free C2-ceramide as single agent was investigated 
in various AML cell lines representing different subtypes, KG-1 (M1), HL-60 
(M2), NB4 (M3), U937 (M5), MV4-11 (M5) and HEL (M6), as well as K562, a 
cell line of blast crisis of chronic myelogenous leukemia (BC-CML). 
Concentration dependent decrease in leukemic cell viability after 72h exposure to 
free C2-ceramide was observed, with IC50 values within the same order of 
magnitude in various cell lines (Table 18 and Suppl. Figure 3). The results also 
demonstrated that free C2-ceramide was less potent than free safingol, whereby 
free C2-ceramide had higher IC50 values.  
 
Table 18. IC50 of free C2-ceramide in various leukemia cell lines. 
Cell viability was determined using MTT assay and subsequently analyzed by 
CalcuSyn software to estimate IC50 values. Data are mean ± S.E.M obtained from 
three independent experiments. Values are expressed in 2 significant figures. R 
values are in parentheses, and represent the goodness of fit of the data.  
 
Cell line Classification/ Diagnosis IC50 (µM) 
KG-01  M1 36 ± 2.3 (0.92) 
HL-60  M2 52 ± 1.6 (0.95) 
NB4  M3 30 ± 2.1(0.92) 
U937  M5 44 ± 4.2 (0.99) 
MV-4-11 M5 27 ± 3.8 (0.93) 
HEL  M6 39 ± 3.2 (0.92) 
K562  BC-CML 37 ± 2.2 (0.97) 
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Next, U937 and HL-60 cells were treated with free safingol in 
combination with free C2-ceramide at 4:1, 1:1 and 1:4 molar ratios, and 
subsequently evaluated for cell viability and C.I. by MTT assay and CalcuSyn 
software, respectively. ED90 is defined as the effective dose to achieve 90% 
leukemia cell kill. According to the recommended description for presenting the 
degree of synergism as described in Table 5, the effect of combining free safingol 
and free C2-ceramide at their ED90 was slightly synergistic or nearly additive at 
1:1 molar ratio (Table 19). In contrast, the effect of combining free safingol and 
free C2-ceramide at ED90 was nearly additive or antagonistic at 4:1 and 1:4 molar 
ratios. 
 
Table 19.  IC50 and C.I. of free safingol/C2-ceramide combination at different 
molar ratios in U937 and HL-60 leukemia cell lines. 
a Cell viability was determined using MTT assay. IC50 and C.I. were calculated 
using CalcuSyn software. Data are mean ± S.E.M obtained from three 
independent experiments. Values are expressed in 2 significant figures. R values 
are in parentheses, and represent the goodness of fit of the data.  
b Combination index (C.I.) at ED90. 
 
These data suggested that 1:1 molar ratio of free safingol/C2-ceramide 
combination was more beneficial in killing AML cells than the other molar ratios. 
This fixed molar ratio was further tested in five other AML cell lines representing 
Molar ratio of 
safingol to C2-
ceramide 
IC50a (µM) C.I.b 
U937 HL-60 U937 HL-60 
4:1 3.3 ± 0.2 (0.95) 0.93 ± 0.3 (0.98) 0.93 ± 0.3 (0.98) 1.2 ± 0.2 (0.99) 
1:1 3.1 ± 0.5 (0.98) 1.0 ± 0.1 (0.95) 1.0 ± 0.1 (0.95) 0.89 ± 0.2 (0.92) 
1:4 3.2 ± 0.3 (0.95) 1.2 ± 0.3 (0.95) 1.2 ± 0.3 (0.95) 1.6 ± 0.1 (0.99) 
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different AML subtypes. As shown in Table 20, the C.I. values for free 
safingol/C2-ceramide combination at 1:1 molar ratio in seven AML cell lines 
were nearly additive or synergistic at ED90.  
 
Table 20.  IC50 and C.I. of free safingol/C2-ceramide combination at 1:1 molar 
ratios in various AML cell lines. 
a Cell viability was determined using MTT assay. IC50 and C.I. were calculated 
using CalcuSyn software. Data are mean ± S.E.M obtained from three 
independent experiments. Values are expressed in 2 significant figures. R values 
are in parentheses, and represent the goodness of fit of the data.  
b Combination index (C.I.) at ED90. 
 
Cell cycle status of NB4 and U937 cells were determined after 12 h and  
48 h treatment, respectively. Both cell lines were treated with 10 µM of free 
safingol, 10 µM of free C2-ceramide or 10 µM of free safingol/C2-ceramide 
combination at 1:1 molar ratio (containing 10 µM of safingol and 10 µM of C2-
ceramide). Safingol induced significant increase in the sub-G0/G1 fraction in both 
cell lines, as compared to control (Figure 20). The percentage of cells in the sub-
G0/G1 phase represented the apoptotic fraction. Of note, free safingol/C2-
ceramide combination at 1:1 molar ratio as compared to free safingol induced 
Cell line Classification/ Diagnosis IC50
a
 (µM) C.I.b 
KG-01 M1 3.5 ± 0.2 (0.95) 1.0 ± 0.1 (0.95) 
HL-60 M2 3.2 ± 0.2 (0.92) 0.89 ± 0.2 (0.92) 
NB4 M3 1.9 ± 0.1 (0.94) 0.95 ± 0.3 (0.95) 
U937 M5 3.3 ± 0.2 (0.95) 1.0 ± 0.1 (0.95) 
MV4-11 M5 2.5 ± 0.7 (0.90) 0.85 ± 0.1 (0.92) 
HEL M6 3.0 ± 0.2 (0.90) 0.43 ± 0.1 (0.92) 
K562 BC-CML 4.5 ± 0.9 (0.99) 0.93 ± 0.2 (0.92) 
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further increased in the sub-G0/G1 fraction in both cell lines (p<0.005, comparing 
free drug combination with vehicle control; p<0.05, comparing free drug 
combination with free safingol). These data further demonstrated the therapeutic 
synergism of this bioactive lipid combination, whereby the effect of safingol and 
C2-ceramide in combination is greater than that achieved with either drug alone 
under identical treatment conditions (U937: 39% for safingol/C2-ceramide 
combination versus 19% and 6% for safingol alone and C2-ceramide alone, 
respectively; NB4: 52% for safingol/C2-ceramide combination versus 31 % and 





Figure 20. Percentage of (A) U937 and (B) NB4 cells in various phases of the cell 
cycle after treated with 10 µM of safingol, C2-ceramide or safingol/C2-ceramide 
combination at 1:1 molar ratio. U937 and NB4 cells were stained with propidium 
iodide after treated for 48 h and 12 h, respectively, followed by cell cycle analysis 
using flow cytometry. The bar graph indicated the percentage of cell number in 
each cell cycle phase. Data are mean ± S.E.M obtained from three independent 
experiments. Ethanol was used as vehicle control. (*p<0.05, compared to control; 
**p<0.05, compared to free safingol). 
 
4.3.2.2. Downregulation of cell cycle-related genes played an important role 
in the synergistic mechanism of safingol/C2-ceramide combination 
To have a better understanding of the full potential of combination therapy, 
microarray-based approach was used to identify the potential molecular targets 




the gene expression between treated and control cells. U937 and NB4 cells were 
treated with 10 µM of free safingol, 10 µM of free C2-ceramide or 10 µM of free 
safingol/C2-ceramide combination. Three separate lists of genes with >1.6 fold-
change (FC) in the expression level that were unique to free safingol/C2-ceramide 
combination therapy in both cell lines were generated: 1) early gene expression 
profiles of NB4 and U937 cells treated for 6 h and 12 h, respectively; 2) late gene 
expression profiles of NB4 and U937 cells treated for 12 h and 24 h, respectively; 
and 3) gene expression profiles in both cell lines treated for 12 h (Suppl. Table 1).  
The traditional way of analyzing individual gene expression has several 
limitations. Genes that are only moderately changed could be overlooked, and it 
may be difficult to find significant change by looking at each gene separately. 
More importantly, it could be an interesting and important finding if many genes 
belonging to the same gene set are changed, even moderately. Hence, we assessed 
the differences in gene expression profile between combination therapy and 
vehicle control using gene-set enrichment analysis (GSEA). GSEA is a 
computational method that determines whether an a priori defined set of genes 
shows statistically significant, concordant differences between two biological 
states (in this case combination therapy versus control) [197]. A list of gene sets 
enriched in U937 and NB4 cells with a false discovery rate (FDR) of <0.05 and a 
nominal p-value of <0.01 was generated (Suppl. Table 2). Normalized enrichment 
score (NES) is the primary statistic for examining gene set enrichment results 
which expresses the degree to which a gene set is overrepresented at the top or 
bottom of a ranked list of genes after normalization across analyzed gene sets 
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[197]. The negative NES indicates that the gene set in combination therapy 
treatment group is down-regulated as compared to control.  
From Suppl. Table 2, some of the gene sets involved in cancer metastasis, 
DNA repair and cell proliferation were negatively enriched, and a large number of 
cell cycle-related gene sets were down-regulated in U937 and NB4 cells treated 
with free safingol/C2-ceramide combination. From the leading-edge subset of five 
highly enriched cell cycle-related gene sets (Suppl. Figure 4), Cdc25A, PRMT5 
and MYC were genes that were also found in Suppl. Table 1. The leading-edge 
subset represents core genes of a gene set that accounts for the enrichment signal. 
MYCBP, one of the gene in Suppl. Table 1, was also included for subsequent 
analysis as it regulates the transcriptional activity of MYC by stimulating the 
activation of E-box-dependent transcription by MYC [198]. Western blot analysis 
was conducted to study the changes in protein expression of these selected genes, 
so as to further support their functional roles in the synergistic mechanism at the 
protein level. From Figure 21, the western blot results supported the findings of 
the microarray study where free safingol/C2-ceramide combination down-
regulated PRMT5, MYC, Cdc25A and MYCBP at the protein level, particularly 
at late time points for each cell line as compared to other treatment groups. In 
addition, the free safingol/C2-ceramide induced the expression of p53 in U937 
and NB4 cells (Figure 21), which was generally known for its roles in maintaining 




   
       
Figure 21. Down-regulation of PRMT5, MYC, Cdc25A, MYCBP and p53 in 
U937 and NB4 cells. Cells were treated with 1) vehicle control (ethanol), 2) free 
safingol, 3) free C2-ceramide and 4) free safingol/C2-ceramide combination for 
the indicated time. Protein lysates were assayed by western blotting and β-actin 
was used as the loading control. All blots shown are representative of three 
independent experiments.  
 
4.3.3. Section discussion 
Combination-based chemotherapy has been used as the first-line therapy 
for many hematological cancers and solid tumors in clinical practice. It offers the 
advantages of simultaneously targeting multiple cancer survival pathways, and 
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thereby increasing the efficacy of chemotherapeutic drug as well as reducing the 
potential of resistance development. In this section, we aimed to develop a 
bioactive lipid combination of safingol and C2-ceramide at a synergistic molar 
ratio to achieve enhanced anti-leukemic activity. 
Our results have demonstrated that safingol/C2-ceramide combination at 
1:1 molar ratio was synergistic in a wide range of AML cell lines. The cell cycle 
analysis results also supported the findings of C.I. analysis where 1:1 molar ratio 
of safingol and C2-ceramide was synergistic in these AML cell lines, as reflected 
by the significant increase in the sub-G0/G1 fraction. Our data also suggest that 
the synergism of combination therapy could be due to down-regulation of cell-
cycle related genes, namely PRMT5, MYC, MYCBP and Cdcd25A, which was 
subsequently confirmed by western blotting.  
Deregulation of the MYC oncogene family is one of the most frequent 
events associated with solid tumors and leukemia [199]. Overexpression of MYC 
plays a critical role in the myeloid leukemogenesis, as evidenced by the rapid 
induction of myeloid leukemia in mouse models overexpressing MYC in the 
myeloid  progenitors[200]. Of note, it is generally known that MYC could impair 
p53-mediated apoptosis in leukemic cells [201]. p53 protein is a tumor suppressor 
protein that regulates important cellular processes[202, 203]. For instance, 
activation of p53 in response to DNA damages or stress signals will lead to 
apoptosis or cell-cycle arrest. MYCBP is a transcriptional cofactor of MYC that 
could stimulate the activation of E box-dependent transcription by MYC. The use 
of MYC as the molecular target of various types of hematological malignancies 
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and solid tumors, including AML has been intensely investigated over the past 
few years [204-206]. Recently, a number of small-molecule MYC inhibitors, 
including JQ-1 and 10058-F4 have demonstrated promising anti-leukemia activity 
in AML cell lines, primary cells and preclinical animal models [204, 207]. 
However, the in vivo data of these MYC inhibitors have been less encouraging, 
possibly due to unfavorable pharmacokinetics profile, resulting in rapid 
elimination from the bloodstream [208]. Moreover, CX-3543 (Quarfloxin), a 
MYC inhibitor that had reached Phase II clinical trials for the treatment of 
neuroendocrine/carcinoid tumours, did not proceed further to phase III due to 
poor bioavailability[209]. These findings further demonstrate the importance of 
an appropriately designed drug delivery system in translating in vitro observations 
of promising drug compounds into in vivo and clinical efficacy. 
Overexpression of PRTM5 has been found in a wide range of human 
cancer cell lines and primary cells, including gastric, leukemia and lymphoid 
cancers [210, 211]. PRMT5 was involved in the transcriptional repression of 
tumor suppressor protein p53, whereby down-regulation of PRMT5 would trigger 
cell-cycle arrest in G1 or p53-dependent apoptosis [212, 213]. Lastly, Cdc25A is 
an important regulator of the cell-cycle, and up-regulation of cdc25A has been 
found in many solid tumors, particularly in breast and head and neck cancers 
[214]. It has been suggested that Cdc25A is one of the transcriptional target of 
MYC [214-217]. In addition, p53 was significantly up-regulated by safingol/C2-
ceramide combination, which in turn, indicated that the synergism observed could 
result from enhanced p53-mediated apoptosis. Based on these findings, we 
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propose a model depicting the possible mechanism of synergy of the safingol/C2-
ceramide combination in AML cells (Figure 22).  
 
 
Figure 22. Proposed model depicting the mechanism of synergy of safingol and 
C2-ceramide combination in U937 and NB4 cells. 
 
In summary, the current data suggests that 1:1 molar ratio of safingol/C2-
ceramide combination could induce down-regulation of these cell cycle-related 
genes which eventually leads to an increase in p53-mediated apoptosis. These 
observations will help define the optimal chemotherapy for future clinical trials in 
AML. The results of liposomal safingol in previous section provide important 
findings on the liposome design that could serve as a platform for the delivery of 
safingol-based combination therapy. The development of a liposomal formulation 
that incorporated the bioactive lipid combination of safingol and C2-ceramide 
based on the design of liposomal safingol will be studied in the next section. 
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4.4. Liposomal formulation of the combination of safingol and C2-ceramide 
for the treatment of AML 
4.4.1. Section overview 
The synergistic anti-leukemia activity of the bioactive lipid combination 
of safingol and C2-ceramide at 1:1 molar ratio has been demonstrated in vitro in 
previous section. However, the translation of this promising drug combination 
into clinical use faces significant challenges due to their hydrophobicity and 
hemolytic toxicities of the lipids. Moreover, it is important to maintain the 
synergistic drug ratio of safingol and C2-ceramide in vivo given the inherently 
different pharmacokinetics of the individual lipids.  
In view of the above issues associated with combination therapy, many 
strategies including liposome delivery systems were developed to achieve 
maximum therapeutic effect from a particular drug combination. In section 4.2, a 
liposomal formulation of safingol was developed that had significantly improved 
the therapeutic efficacy in AML while reduced the hemolytic toxicity of safingol. 
Furthermore, liposomes have been the most advanced in the development of drug 
combination product for cancer therapy, with liposomal cytarabine:daunorubicin 
co-encapsulated formulation (CPX-351) representing one such example which has 
entered into Phase III clinical trial for AML [178]. In this section, the same 
formulation strategy in the development of liposomal safingol was applied to 
develop the liposomal formulation that would incorporate safingol and C2-
ceramide at 1:1 molar ratio for the treatment of AML. This section was aimed to 
evaluate the anti-leukemia activity of this liposomal formulation in AML cell 
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lines, primary AML cells and human AML xenograft model in SCID mice. It was 
demonstrated here that the synergistic anti-leukemia activity of safingol and C2-
ceramide combination could be achieved in vivo by formulating this bioactive 
lipid combination into an appropriately designed liposome. 
 
4.4.2. Section results 
4.4.2.1. Development of liposomal C2-ceramide and liposomal safingol/C2-
ceramide 
In this section, the main aim was to develop a liposomal formulation that 
incorporates safingol and C2-ceramide efficiently for therapeutic evaluation and 
alongside, a liposomal formulation for C2-ceramide was developed to allow 
comparison. The incorporation of C2-ceramide or the combination of safingol and 
C2-ceramide was done based on the passive incorporation method as described 
previously for liposomal safingol in section 4.2. From Figure 23A, up to 10 mol% 
C2-ceramide could be incorporated in DSPC/CHOL based liposomes, with 
efficiencies >90%. Based on the same formulation strategy, safingol and C2-
ceramide were passively loaded at 1:1 molar ratio during film formation to form 
liposomal safingol/C2-ceramide. The incorporation efficiency was >90% when 
safingol and C2-ceramide were incorporated at 5 or 7.5 mol% each; however, the 
incorporation efficiencies significantly decreased to 67% and 53% for safingol 
and C2-ceramide, respectively, when the total mol% of bioactive lipids was 
increased to 20 mol% (Figure 23B). As such, liposomal C2-ceramide at 7.5 mol% 
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and liposomal safingol/C2-ceramide combination at 7.5:7.5 mol% were used for 
all subsequent studies. 
Figure 23. Incorporation efficiencies of (A) liposomal C2-ceramide and (B) 
liposomal safingol/C2-ceramide at different mol%. Results shown are means ± 
SEM from three independent experiments. (*p<0.05, compared to 5:5 mol%; 
**p<0.05, compared to 7.5:7.5 mol%). 
 
According to the shape hypothesis of lipid polymorphism as discussed in 
section 1.6.2.1 [117], the presence of single aliphatic chain and/or inverted-cone 
shaped lipids at high concentrations in DSPC liposomes could result in non-
bilayer structures [218]. As such, cryo-TEM studies were performed, and the 
images confirmed that incorporating safingol and C2-ceramide at a total lipid 
content of 15 mol% did not change the liposome morphology (Figure 24). The 
formulation characteristics of liposomal C2-ceramide and liposomal safingol/C2-
ceramide were summarized in Table 21. No significant difference in size, 
polydispersity, zeta potential and drug content was observed over the working 
period of 7 days when the liposomes were kept at 4°C. Of note, liposomal C2-
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ceramide had a negative zeta potential of -4.74 ± 1.1 mV, while the zeta potential 
of liposomal safingol/C2-ceramide was positive with a value of +45.4 ± 0.96 mV. 
       
Figure 24. Cryo-TEM images of (A) empty DSPC/CHOL liposomes, (B) 
liposomal C2-ceramide and (C) liposomal safingol/C2-ceramide (1:1 molar ratio). 




















































































As shown in Figure 25A and 25B, liposomal C2-ceramide and liposomal 
safingol/C2-ceramide provided sustained drug release over 48 hours when 
incubated with 50% v/v fetal bovine serum at 37°C. Square-root-of-time release 
model was the best-fitted model for liposomal C2-ceramide with correlation 
coefficient (r) of 0.82, as compared to the other two release models, namely zero-
order (r=0.71) and first-order (r=0.64). This finding suggested that diffusion is the 
primary mechanism of C2-ceramide release from the liposome bilayer, similar to 
the drug release kinetics of liposomal safingol in section 4.2. On the other hand, 
incorporation of safingol modified the drug release kinetics of C2-ceramide in 
liposomal safingol/C2-ceramide combination to the first order model. The first 
order model gave the best fit for safingol (r=0.98) and C2-ceramide (r=0.97), 
suggesting that the rate of drug release is dependent on the concentration of the 
drugs present within the bilayer of the liposomes. More importantly, no 
significant difference was observed in the safingol:C2-ceramide concentration 
ratios, implying that the 1:1 molar ratio was maintained in the liposomes over    
48 h in the presence of serum (Figure 25C).  
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Figure 25. Drug release profiles of (A) liposomal C2-ceramide and (B) liposomal 
safingol/C2-ceramide (1:1 molar ratio) when incubated with 1:1 (v/v) fetal bovine 
serum at 37ºC over 48 hours. (C) The safingol to C2-ceramide concentration ratio 
in liposomal safingol/C2-ceramide was maintained at 1:1 molar ratio over 48h in 
the presence of serum. Each reported value represents the mean ± SEM from three 
independent experiments. 
 
To demonstrate that liposome incorporation can attenuate the hemolytic 
toxicities of the bioactive lipids, red blood cells harvested from rat whole blood 
were incubated with the bioactive lipids in free or liposomal forms.  As shown in 
Figure 26, the hemolytic propensities of free C2-ceramide or free safingol/C2-
ceramide combination were concentration-dependent, and could be significantly 
reduced via liposome incorporation.  This is in line with our previous study in 
 117 
 
Section 4.2.2.3, whereby liposomal delivery of bioactive lipids presented a viable 
solution to the long-standing problem of hemolytic toxicities. 
 
 
Figure 26. Hemolysis study of (A) liposomal C2-ceramide and (B) liposomal 
safingol/C2-ceramide (1:1 molar ratio). Percentages of hemolysis of free drugs ( ♦) 
were compared to liposomal formulation ( ■) after incubation with 4% v/v red 
blood cells for 20 h at 37°C. Positive control used was sterile water while 
negative control was HBS. Ethanol was used as the vehicle control for free drug. 
DSPC/CHOL empty liposome without drug was used as the lipid control. Each 
reported value represents the mean ± SEM from three independent experiments  
(* p<0.05, compared to free drugs). 
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4.4.2.2. In vitro evaluation of anti-leukemic activity of liposomal C2-ceramide 
and liposomal safingol/C2-ceramide 
Anti-leukemic activities of the liposomal formulations were first evaluated 
using a panel of human leukemic cell lines and primary patient samples before 
proceeding to in vivo evaluation. From Table 22, the concentrations for liposomal 
C2-ceramide to achieve 50% cell kill in the various cell lines were of unusually 
high values (160- >1000 µM), whereas the IC50 values of the free form tested in 
the same panel of cell lines ranged from 27–52 µM (Table 18; page 96). This 
indicates that incorporation of C2-ceramide into liposomes compromised its 
potency in various AML cell lines.  In contrast, all AML cell lines responded well 
to the treatment of liposomal safingol/C2-ceramide combination, with IC50 values 
ranging from 1.5–11 µM (Table 22), and dose-dependent decrease in AML cell 
viability was observed after 72 h of treatment of the liposome combination (Suppl. 
Figure 5). Of note, the IC50 values of liposomal safingol/C2-ceramide were 
generally lower than that of liposomal safingol. In particular, the IC50 value of 
liposomal safingol/C2-ceramide in U937 cell line was significantly lower by 3 
folds, as compared to liposomal safingol. Hence, U937 cell line will be used to 





Table 22. IC50 of liposomal safingol, C2-ceramide and liposomal safingol/C2-
ceramide (1:1 molar ratio) in various leukemia cell lines. 
a Cell viability was determined using MTT assay and subsequently analyzed by 
CalcuSyn software to estimate IC50 values. Data are mean ± S.E.M obtained from 
three independent experiments. Values are expressed in 2 significant figures. R 
values are in parentheses, and represent the goodness of fit of the data. (*p<0.05, 
comparing with liposomal safingol). 
b Data was adapted from Table 13 to allow comparison. 
 
Examining the formulation characteristics, including incorporation 
efficiencies and drug release kinetics, of liposomal C2-ceramide and liposomal 
safingol/C2-ceramide combination showed no significant differences except for 
their zeta potentials.  Stemming from our previous observation that zeta potential 
could be important to cellular uptake of liposomal formulation as described in 
section 4.2, it was postulated that the differences in the anti-leukemic activities 
between liposomal C2-ceramide and liposomal safingol/C2-ceramide combination 
could possibly be attributed to lower cellular uptake of C2-ceramide as a result of 
liposome incorporation.  Indeed, our cellular uptake study presented in Figure 27 
demonstrated a lack of internalization of liposomal C2-ceramide, whereas 
Cell line Classification/ Diagnosis 







KG-01 M1 7.3 ± 0.4 (0.99) >1000 7.4 ± 1.3 (0.94) 
HL-60 M2 7.5 ± 0.8 (0.92) 160 ± 20 (0.96) 5.3 ± 0.2 (0.97)* 
NB4 M3 1.5 ± 0.2 (0.96) >1000 1.5 ± 0.1 (0.98) 
U937 M5 10 ± 1.6 (0.97) 700 ± 80 (0.95) 3.7 ± 0.4 (0.97)* 
MV-4-11 M5 6.1 ± 0.9 (0.99) 560 ± 44 (0.96) 4.5 ± 0.7 (0.98) 
HEL M6 10 ± 0.3 (0.99) >1000 7.1 ± 1.0 (0.95)* 
K562 BC-CML 13 ± 4.8 (0.98) >1000 11 ± 3.7 (0.98) 
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liposomal safingol/C2-ceramide showed significant cellular accumulation as a 
function of time. 
 
 
Figure 27. Cellular accumulation of liposomal C2-ceramide and liposomal 
safingol/C2-ceramide (1:1 molar ratio). U937 cells were treated with 20 µM DiI-
labeled liposomal formulations for 4 and 24 h. Representative images from three 
independent experiments were shown, and were taken using Olympus FluoView 
FV1000 microscope at ×60 objective magnifications. The overlay images were 
merged images of Differential Interference Contrast and DiI channels, and the 3D 
images were processed from z-stacks of 0.78 µm using Imaris 7.2.3 software. 
 
To further support our findings in leukemic cell lines, primary leukemia 
cells obtained from AML patients were treated with 0.625–20 µM liposomal 
safingol/C2-ceramide for 72 h. The IC50 values of liposomal safingol/C2-
ceramide in primary leukemia cells were of the same order of magnitude as those 
observed in the leukemia cell lines, with dose-dependent decrease in cell viability 
and IC50 values ranging from 3.9–7.2 µM (Suppl. Figure 6 and Table 23). These 
results provide further evidence for the clinical potential of liposomal 
safingol/C2-ceramide in the treatment of AML.  
Liposomal C2-ceramide Liposomal safingol/C2-ceramide  
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Table 23. IC50 of liposomal safingol/C2-ceramide (1:1 molar ratio) in primary 
leukemia cells from AML patients. 
Cell viability was determined using MTT assay and subsequently analyzed by 
CalcuSyn software to estimate IC50 values. Data are mean obtained from one 
independent experiment done in triplicates. Values are expressed in 2 significant 
figures. R values are in parentheses, and represent the goodness of fit of the data.  
 
4.4.2.3. The synergistic drug ratio of safingol and C2-ceramide combination 
was maintained in vivo through liposome incorporation 
Safingol was more potent than C2-ceramide in AML cells and the MTD of 






Diagnosis Karyotype IC50  (µM) 
AML-P1 69/F M1-AML 48,XX,+8,t(9;22)(q34;q11.2), +19[20] 4.1 (0.99) 
AML-P2 48/M M2-AML 46,XY[18] 4.0(0.98) 
AML-P3 37/M M2-AML 46,XY[20] 4.5 (0.99) 
AML-P4 38/F M3-AML 46,XX,t(15;17)(q22;q21)[19]/46, XX[1] 4.2 (0.99) 
AML-P5 32/M M4-AML 46,XY[20] 5.2 (0.99) 





















47,XY,+8[13]/46,XY[7] 7.2 (0.99) 
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administered in the animal studies was matched with the MTD of free safingol 
(40 mg/kg in mouse) [54]. In addition, a lower drug dose of liposomal 
safingol/C2-ceramide was used in the pharmacokinetic study and in vivo efficacy 
study so as to evaluate the dose reduction benefit of this synergistic bioactive lipid 
combination in vivo. 
Plasma elimination profile of liposomal C2-ceramide was determined in 
female Balb/c mice after an intravenous bolus dose at 40 mg/kg of C2-ceramide. 
Similarly, plasma elimination profile was obtained for liposomal safingol/C2-
ceramide combination (1:1 molar ratio) which contained a drug dose of 26.7 
mg/kg for safingol and C2-ceramide each. Figure 28A showed that the 
concentration of C2-ceramide in liposome form was undetectable after 4 h, 
whereas the concentrations of safingol and C2-ceramide in the liposomal 
combination remained detectable throughout the 24-h course of study. Data from 
the plasma elimination profiles of the two liposomal formulations were 
subsequently analyzed using the WinNonlin software to estimate the 
pharmacokinetic parameters based on non-compartmental analysis, with results 
summarized in Table 24. Of note, C2-ceramide was eliminated rapidly from 
bloodstream when administered as a single agent in liposome form, with 8-fold 
increase in clearance in comparison to C2-ceramide administered in the liposomal 
safingol/C2-ceramide combination. Other pharmacokinetic parameters such as 
MRT and AUC also supported this finding.  
 The concentration ratio of the individual drugs of a combination is known 
to have significant effect on its anti-leukemic activity as discussed in section 1.4. 
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Therefore, it is imperative to investigate if there was a shift in the molar ratio of 
safingol:C2-ceramide in vivo. From figure 28B, the 1:1 molar ratio of 
safingol:C2-ceramide was shifted to approximately 2:1 after injection into 
bloodstream, suggesting relatively more rapid dissociation of C2-ceramide from 
the liposome than safingol. At 24 h post-injection, the plasma safingol:C2-
ceramide molar ratio shifted to approximately 0.7:1.  In view of the changes in 
these plasma drug molar ratios, further evaluation based on in vitro MTT assay 
was performed to determine if such changes would compromise the synergistic 
effect of safingol/C2-ceramide combination.  Two additional safingol:C2-
ceramide molar ratios of 2:1 and 1:2 were tested in U937 cell line, and the C.I. 
values for the molar ratios of 2:1 and 1:2 were 0.87 ± 0.04 (R2=0.99) and 0.84 ± 
0.08 (R2=0.98), respectively, indicating that both molar ratios were synergistic. 
Taken together, the shifts in the plasma safingol:C2-ceramide ratios presumably 
did not compromise the synergistic anti-leukemic activity of this liposomal 





Figure 28.  (A) Plasma elimination profiles of liposomal C2-ceramide (×), 
safingol in liposomal safingol/C2-ceramide ( ●) and C2-ceramide in liposomal 
safingol/C2-ceramide ( ▲). An intravenous bolus injection of liposomal C2-
ceramide and liposomal safingol/C2-ceramide was given to Balb/c mice at a dose 
of 40 mg/kg and 26.7mg/kg, respectively.  Each time point represents the mean 
plasma drug concentration ± S.E.M obtained from three mice. (B) Changes in 
safingol to C2-ceramide molar ratio in plasma over 24 h. Any point lies within the 
area defined by the two dotted-lines represents synergistic molar ratio.  Each 






Table 24. Pharmacokinetic parameters for liposomal C2-ceramide and liposomal 
safingol/C2-ceramide (1:1 molar ratio) in Balb/c mice. 
a Non-compartmental analysis was used to estimate the various pharmacokinetic 
parameters.  Four and five time points were used for the estimation of the terminal 
elimination phase for liposomal C2-ceramide and liposomal safingol/C2-ceramide, 
respectively. In the calculations, first order elimination was assumed, and uniform 
weighting was used. 
bAUClast, area under curve from time of dosing (t = 0 h) up to the last measured 
concentration (t = 24h); AUMClast, area under moment curve from time of dosing 
up to the last measured concentration; MRTlast, mean residence time which is 
calculated based on values up to the last measured concentration; CL, total body 
clearance; Vss, volume of distribution at steady state; R2, goodness of fit statistic 
for the terminal elimination phase; Corr (x:y), correlation between time (X) and 
log concentration (Y) for the points used in the estimation of the first order rate 
constant associated with the terminal portion of the plasma concentration-time 
curve via linear regression. 
 
  








(µM  h) 
1.41 × 102 1.10 × 103 7.17 × 102 
AUMClast  
(µM  h2) 
8.61 × 101 5.17 × 103 3.28 × 103 
MRTlast (h) 0.61 4.67 4.57 
CL (mL/h) 16.1 1.58 2.10 
Vss (mL) 11.7 7.92 11.5 
R2 0.840 0.998 0.982 
Corr (x:y) -0.916 -0.999 -0.991 
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4.4.2.4. Liposomal safingol/C2-ceramide combination induced complete 
remission in U937-inoculated SCID mice 
U937 xenograft model previously established in section 4.2 was used to 
evaluate the anti-leukemia activity of of liposomal C2-ceramide and liposomal 
safingol/C2-ceramide combination. All mice were first preconditioned with 100 
mg/kg cyclophosphamide intraperitoneally to facilitate engraftment of human 
U937 cells. The inoculated mice were then randomized into the three study 
groups: saline control, liposomal C2-ceramide (drug dose of 40 mg/kg) and 
liposomal safingol/C2-ceramide (drug dose of 26.7 mg/kg for each drug). All 
mice from the saline group showed body weight loss, ruffled fur and paralysis of 
hindlimb during the early course of study and exhibited a MST of 20 days      
(Table 25). In addition, the saline control group exhibited extensive leukemia cell 
infiltration in the BM and PB, as illustrated by the Giemsa-stained PB and BM 
smears (Figure 29). Liposomal C2-ceramide was not able to completely eliminate 
U937 cells in PB and BM, and the MST of mice in this treatment group was 24 
days with 20% ILS. On the other hand, U937 cell number was significantly 
reduced in PB and BM of the mice treated with liposomal safingol/C2-ceramide 
combination, despite a 1.5-fold reduction in drug dose. More importantly, 
liposomal safingol/C2-ceramide was more effective as compared to liposomal C2-
ceramide or liposomal safingol, whereby the MST of the U937-inoculated mice 
was extended to 37 days to yield 85% ILS (Table 25). Of note, two out of six 
U937-inoculated mice treated with liposomal safingol/C2-ceramide survived until 
the end of the study period of 60 days, and had normal WBC counts without 
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circulating blasts (Figure 30), suggesting the achievement of CR in 33% of the 
mice. The definition of complete remission in AML includes normal hematologic 
parameters, < 5% blasts in the marrow, no signs or symptoms of the disease and 
no signs or symptoms of central nervous system leukemia or other extramedullary 
infiltration [219]. Furthermore, no evidence of leukemic cell infiltration to liver, 
spleen, kidney and sternum in mice treated with liposomal safingol/C2-ceramide 
was observed except for one mouse, as opposed to extensive infiltration of these 
organs in mice treated with saline or liposomal C2-ceramide (Figure 31). 
Histopathological examination showed undetectable treatment-related toxicity in 
liver, kidney, spleen and sternum of mice treated with liposomal C2-ceramide and 
liposomal safingol/C2-ceramide, respectively (Figure 31). Furthermore, mice 
treated with liposomal C2-ceramide and liposomal safingol/C2-ceramide did not 
experience significant weight loss as compared to the mice in the saline control 





Figure 29. In vivo efficacy of liposomal C2-ceramide and liposomal safingol/C2-
ceramide (1:1 molar ratio) in U937-inoculated SCID mice. (A) Kaplan-Meier 
survival curves of the U937-inoculated SCID mice over 60 days post inoculation. 
Preconditioned SCID mice were inoculated intravenously with 5×106 cells of 
U937 on day 0. Liposomal safingol (dashed-line), liposomal C2-ceramide (dotted-
line) and liposomal safingol/C2-ceramide (dot-dashed-line) were administered 
intravenously at 40 mg/kg, 40 mg/kg and 26.7 mg/kg, respectively. Mice from the 
control group (continuous-line) were given normal saline in the same way. (B) 
Evaluation of U937 cell infiltration (arrow) in PB and BM of the SCID mice 
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treated with liposomal C2-ceramide and liposomal safingol/C2-ceramide (1:1 
molar ratio) at the end point of the study. PB and BM smears were stained with 
modified Wright-Giemsa. Representative images of PB and BM smears from each 
group were shown. Magnifications were 400× for all the images, except for 
images of liposomal C2-ceramide and BM image of liposomal safingol/C2-
ceramide which were captured at 600x.  
 
Table 25. Median survival time, increased median lifespan, percentage of weight 
loss at nadir and long term survivor of U937 human leukemia xenograft model in 
SCID mice (n = 6). 












Saline control N.A. 20 N.A. 7.37 ± 1.50 0/6 
Liposomal safingolg 40 31
e
 55 1.72 ± 1.53
e
 0/6 
Liposomal C2-ceramide 40 24
e




ceramide (1:1 molar ratio) 26.7 37
e,f
 85 2.31 ±2.21
e
 2/6 
a  MST = Median survival time.  
b  Percent increase in life span (% ILS) = (MST of treatment group – MST of 
saline control) / MST of saline control ×100%. 
c Percentage weight loss at nadir = (Weight at nadir - Initial weight before 
treatment) / Initial weight before treatment ×100%. 
d  Long term survivor (LTS) = Number of survivors at the end of the study period 
of 60 days out of 6 U937-inoculated mice. 
e  P <0.05, statistically significant difference as compared to the control group. 
f P<0.005, statistically significant difference as compared to liposomal C2-
ceramide. 




Figure 30.  Effect of liposomal C2-ceramide and liposomal safingol/C2-ceramide 
(1:1 molar ratio) on the number of leukocyte in peripheral blood of mice. Venous 
blood of mice was obtained by cardiac puncture at the predefined endpoints of the 
study and the number of leukocyte was determined using a hematology analyzer. 
Each reported value represents the mean ± SEM obtained from six mice (*p<0.05, 


































































































































4.4.3. Section discussion  
The field of sphingolipid research has received considerable interest 
recently. In particular, sphingosines and ceramides have been identified as 
important bioactive lipids with anti-cancer activity [73]. To date, the effectiveness 
of these bioactive lipids remains limited due to their hydrophobicity and dose-
limiting toxicity of hemolysis. Liposome incorporation of safingol was proven to 
be a promising formulation strategy in enhancing its anti-leukemia activity while 
overcoming the issues associated with free drug of safingol as described in section 
4.2. In order to further improve the therapeutic efficacy of safingol in vivo, a 
synergistic 1:1 molar ratio of safingol and C2-ceramide combination was 
identified in previous section. In this section, a liposomal formulation that 
incorporates safingol and C2-ceramide at the synergistic molar ratio was 
developed and subsequently evaluated for its in vitro and in vivo anti-leukemia 
activity. This liposomal formulation of safingol and C2-ceramide was shown to be 
effective on various AML cell lines, primary cells and xenograft mouse model, 
while significantly reduced the hemolytic toxicity of the free drugs through 
liposome incorporation. 
From the formulation perspective, our results further demonstrated the 
importance of positive zeta potential of DSPC-based liposomes for AML cellular 
interactions described in section 4.2. Incorporation of C2-ceramide into 
DSPC/CHOL liposome was attempted to enhance the delivery of C2-ceramide to 
AML cells. However, our results demonstrated that liposomal C2-ceramide not 
only provided no therapeutic advantage, but also compromised the anti-leukemic 
activity as compared to free drug. We were able to correlate the abrogation of 
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anti-leukemic activity with the lack of internalization of liposomal C2-ceramide 
into AML cells correspond to the negative zeta potential of the liposomes. In 
contrast, liposome incorporation of safingol/C2-ceramide combination did not 
compromise the anti-leukemia activity and showed significant accumulation of 
the liposomes within the AML cells. Safingol, not only acted as an anti-leukemia 
agent to synergize with C2-ceramide in this study, but also modified the 
liposomal characteristics, including zeta potential, which is crucial for promoting 
cellular uptake of liposomes into AML cells. Furthermore, these observations also 
suggested that safingol and C2-ceramide were stably associated with the liposome, 
and they were not readily entered the AML cells via lipid exchange from the 
liposome bilayer to the cell membranes. Although this aspect of the results was 
not investigated further, it would be interesting to find out the localization of the 
drugs and liposomes within the cells using radiolabeled bioactive lipids and bulk 
liposomal lipids to better understand the cellular uptake of these formulations. 
Besides, a drastic decrease in the incorporation efficiency was observed when 
safingol and C2-ceramide were incorporated into the liposome at 10 mol% each. 
Based on the incorporation efficiency data, it was estimated that the maximum 
total mol% of safingol and C2-ceramide that could be loaded was 15mol% 
without compromising the incorporation efficiency. Our results are in line with 
the findings of several studies whereby ≤15mol% of single aliphatic chain and/or 
inverted-cone shaped lipids could be incorporated into DSPC/CHOL liposome 
[38, 220, 221]. This could be due to destabilization of membrane bilayer as a 
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consequence of micelles or other non-bilayer structures formation by these 
bioactive lipids [218, 222].  
One of the major advantages of having synergistic drug combination is to 
reduce the dose of the individual drugs to minimize dose-dependent toxicities 
while maintaining maximum cancer cell kills [178]. In this section, liposomal 
safingol/C2-ceramide was administered at two-third of the MTD of safingol, 
whereby safingol was known to exhibit dose-limiting hemolytic toxicity in pre-
clinical models [54]. From our in vivo efficacy study, although mice from all 
treatment groups showed an increase in lifespan, only two out of six mice treated 
with liposomal safingol/C2-ceramide combination survived at the end of the 60 
days efficacy study. Of note, it was demonstrated that liposomal safingol/C2-
ceramide was more effective than liposomal safingol or liposomal C2-ceramide 
alone even at two-third of the MTD of safingol, as reflected by higher %ILS, blast 
cell clearance in PB and BM, non-detectable metastasis in major organs and 
restoration of normal blood count. Considering the pharmacokinetics data from 
this study, the enhanced anti-leukemia activity of liposomal safingol/C2-ceramide 
could be due to the maintenance of the synergistic ratio of safingol and C2-
ceramide combination in plasma over 24 h. Furthermore, the plasma 
concentrations of safingol and C2-ceramide in mice treated with liposomal 
safingol/C2-ceramide combination were much higher than the concentration 
needed to achieve 50% cell kill in U937 cells over  20 h.  
Taken together, these results clearly demonstrate the therapeutic potential 
of a bioactive lipid combination of safingol and C2-ceramide loaded into an 
 135 
 
appropriately designed liposome to deliver the synergistic 1:1 molar ratio to AML 
cells. These results provide the basis for the development of synergistic bioactive 






Chapter 5. Concluding discussion and future directions 
 AML is a deadly hematological cancer of the bone marrow that has no 
adequate standard of care, especially in older patients who are 65 years of age and 
above [223]. The work presented in this thesis comprises a series of experiments 
designed to test the hypothesis that incorporating the bioactive lipid combination 
of safingol and C2-ceramide into liposomes can be used as a therapeutic approach 
to achieve synergistic anti-leukemia activity in AML. In section 4.1, a validated 
LC/MS/MS method which was instrumental in determining the concentration 
ratio of this bioactive lipid combination in vivo was established. Our data 
presented in section 4.2 clearly demonstrated the anti-leukemic activity of 
safingol as a single agent in liposome form. Subsequently, further improvement in 
therapeutic activity was brought about by means of combining safingol and C2-
ceramide at the synergistic 1:1 molar ratio as described in section 4.3. Lastly, 
results presented in section 4.4 suggested that appropriately designed liposomes 
could efficiently incorporate safingol and C2-ceramide so as to achieve 
synergistic therapeutic effect in the treatment of AML. The data provided proof of 
concept evidence and support further development of such liposomes that 
incorporate bioactive lipids for the treatment of AML. Several important findings 
from the formulation and clinical perspectives of the liposome will be discussed 
here, with a particular focus on the future directions. 
 The results presented in section 4.2 and 4.4 demonstrate that zeta potential 
is a critical liposomal formulation attribute in determining the biological activity 
of bioactive lipids loaded into DSPC-based liposomes in AML. Our results for the 
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first time showed that negatively charged liposome systems would significantly 
reduce the anti-leukemic activity of the bioactive lipids such as safingol and C2-
ceramide. Of importance, our results demonstrated that commonly used liposome 
formulation strategy such as pH gradient drug loading could not be generalized 
for all bioactive lipids. Various physical attributes of the liposomes should be 
carefully evaluated, which may impact the biological performance such as cellular 
uptake of the formulation. Our results have important implications in the design 
of DSPC-based liposomes for bioactive lipids in the future. Neutral or negatively 
charged bioactive lipids at physiological pH would require positively charged 
lipids, such as DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) to be 
incorporated in the liposome bilayer to promote the cellular uptake into AML 
cells, while positively charged bioactive lipids should not be loaded into 
liposomes using pH gradient method that would compromised its biological 
activity.  
Leukemic cells at the sites of origin of AML, peripheral blood and bone 
marrow were shown to be completely eliminated possibly through the increase in 
systemic drug exposure and passive delivery of the formulations to the bone 
marrow. The increase in systemic drug exposure could also be attributed to the 
lipid composition of liposomes and lipid dose used.  The high lipid dose used in 
our studies would result in saturation of the phagocytic cells involved in the 
liposome uptake and removal, leading to the increase in plasma concentrations of 
the liposomes [132, 192]. PC-based liposome with high cholesterol content (40 
mol%) is known to facilitate the delivery of drug compounds to bone marrow via 
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decreased clearance by the bone marrow [191]. Our liposome design could serve 
as the platform for delivering other drug compounds to the bone marrow 
compartment without the need of incorporating complex targeting moiety. While 
the pharmacokinetic results had demonstrated that our formulation was able to 
maintain the synergistic molar ratio of safingol and C2-ceramide combination in 
plasma throughout the 24-h course of study, biodistribution of the formulation, 
particularly in the bone marrow and other major organs/tissues, should be 
evaluated in future studies. The result of the study would provide useful 
information for better understanding the biological performance of the liposomes 
and the possible implications on their metabolism, excretion and toxicity.  
Although liposome delivery system represents a viable approach in 
delivering bioactive lipids and drug combinations, there are several challenges 
including physical and chemical instabilities of liposomes in aqueous dispersion 
to be overcome in order to translate such system into large scale production. 
Instability of liposomes has significant impact on the in vivo performance of the 
liposomes, such as reduced efficacy owning to leakage of encapsulated drug 
during storage. In the present study, 7-day, in-use stability has been demonstrated 
for liposomal safingol, liposomal C2-ceramide and liposomal safingol/C2-
ceramide, whereby no leakage of incorporated drug or alteration in vesicle size 
were observed over the working period of 7 days when the liposomes were kept at 
4°C. To achieve long-term stability, liposomes could be lyophilized such that the 
shelf-life could be extended. It has been demonstrated that lyophilization of 
liposomes could minimize physical and chemical degradation of the vesicles 
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during storage [224, 225]. However, the stresses imposed on the liposomes during 
the lyophilization process, including mechanical stress caused by ice crystal 
formation during freezing, might affect the liposomal stability [226, 227]. 
Addition of cryoprotectants such as sucrose, glucose, trehalose, maltose, or 
lactose has been shown to prevent such detrimental effects during the 
lyophilization process of liposomes [228-231]. As the optimal type and amount of 
cryoprotectant used are influenced by the lipid composition of the liposomes, it is 
important to optimize these parameters in order to improve the stability of the 
liposomal formulation of bioactive lipid [230]. In addition, various aspects of the 
lyophilization process, including the effect of lyophilization on the formulation 
characteristic and biological activity of the liposomes should be carefully 
evaluated in the future. 
Improved understanding of the mechanism of synergy at the molecular 
level would facilitate the development of molecularly targeted therapies. The data 
from gene expression profiling and western blot analysis in section 4.3 are the 
first to show genes that are responsible for the synergistic anti-leukemic activity 
of safingol/C2-ceramide combination. One important question to be addressed in 
future studies is the identification of the major contributor to the mechanism of 
synergy among the four genes. This could be done by evaluating the 
pharmacological effect of safingol/C2-ceramide combination in AML cells in 
which individual gene under investigation has been knocked down. If successful, 
this piece of study could provide valuable information of novel drug targets for 
AML in the future. 
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The use of synergistic drug combination is well-known for its ability to 
achieve maximum cancer cell kill with substantial dose reduction of the 
individual drugs to minimize dose-dependent toxicities [178]. In order to capture 
this therapeutic benefit, liposomal safingol/C2-ceramide was administered at two-
third of the MTD of free safingol, whereby safingol was known to exhibit dose-
limiting hemolytic toxicity in pre-clinical models [54]. From our in vivo efficacy 
study, it was demonstrated that liposomal safingol/C2-ceramide was more 
effective than liposomal safingol or liposomal C2-ceramide alone even at two-
third  of the MTD of free safingol, indicating that therapeutic synergism was 
achieved with safingol/C2-ceramide combination at 1:1 molar ratio through 
liposome incorporation. More importantly, the achievement of complete 
remission, an established primary end point for AML drugs [232] in 33% of the 
U937-inoculated mice treated with liposomal safingol/C2-ceramide despite a two-
third fold dose reduction clearly demonstrated the therapeutic potential of this 
bioactive lipids combination. Recently, it has been published after the completion 
of our in vivo study that the MTD of free safingol in human could be as high as 
840 mg/m2 (equivalent to 280 mg/kg in mouse; 7× higher than the dose used in 
our in vivo study) when it was administered as IV infusion over 120 minutes to 
minimize intravascular hemolysis [51]. It is likely that a higher drug dose of 
liposomal safingol/C2-ceramide could be administered such that complete 
remission could be observed in more treated mice. Thus, further evaluation of the 
MTD of liposomal safingol/C2-ceramide combination is warranted in future 
studies. Till date, daunorubicin and cytarabine combination is the standard of care 
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for the treatment of patients diagnosed with AML.  Inclusion of this combination 
regimen in the efficacy study is one area that has not been explored in this thesis. 
It would be interesting to examine if liposomal safingol/C2-ceramide combination 
at 1:1 molar ratio would be equal or superior to standard chemotherapy in vivo. 
Given that this bioactive lipid combination has different mechanisms of action 
than the standard chemotherapy, this rational combination could be of great value 
for the treatment of daunorubicin- and cytarabine-resistant AML.  
Lastly, further studies of liposomal safingol/C2-ceramide combination 
involve comprehensive toxicological study to assess the short term and long term 
toxicity of liposomal safingol/C2-ceramide combination. Liposome incorporation 
of safingol and C2-ceramide could reduce hemolysis in vitro which is the major 
reported side effect, solving the long-standing problem of hemolytic toxicities of 
bioactive lipids. In addition, the dilution effect of the liposomal formulation in 
vivo would further reduce the hemolytic propensities of the bioactive lipids. 
Furthermore, the results of histopathological examination and weight 
measurement clearly demonstrated that minimal treatment-related toxicity was 
observed in mice treated with liposomal safingol/C2-ceramide combination. 
However, further animal toxicological study, including proper blood chemistry 
(ALT, AST, alkaline phosphatase, bilirubin, creatinine, urea and major 
electrolytes) and histopathology, is necessary to fully elucidate the toxicity profile 
of this formulation, as subtle biological and biochemical changes could be 
induced by the treatment. 
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In summary, although this work is preliminary in nature, the work 
presented in this thesis demonstrated that the approach of delivering bioactive 
lipid-based combination using liposomes holds therapeutic promises as a novel 
strategy for AML treatment.  It is anticipated that the development of bioactive 
lipids-based liposomes will facilitate the translation of anti-leukemia activity of 
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Supplementary Figure 1. Cytotoxicity of ( ♦) free and ( ■) liposomal safingol in 
various AML cell lines representing different subtypes, (A) KG-1, (B) HL-60, (C) 
NB4, (D) U937, (E) MV-4-11 and (F) HEL, as well as (G) K562, a cell line of 
blast crisis of chronic myeloid leukemia (BC-CML). Cells were exposed to free or 
liposomal safingol for 72 h. Cell viability was determined by MTT assay. Data 




Supplementary Figure 2. Cytotoxicity of liposomal safingol in primary leukemia 
cells from ten patients. Cells were exposed to liposomal safingol (1.25µM - 20µM) 
for 72 h. Cell viability was determined by MTT assay. Data are mean ± S.D. 





Supplementary Figure 3. Cytotoxicity of free C2-ceramide in various AML cell 
lines representing different subtypes, (A) KG-1, (B) HL-60, (C) NB4, (D) U937, 
(E) MV-4-11 and (F) HEL, as well as (G) K562, a cell line of blast crisis of 
chronic myeloid leukemia (BC-CML). Cells were exposed to free C2-ceramide 
for 72 h. Cell viability was determined by MTT assay. Data are mean ± S.E.M 




Supplementary Table 1. The lists of gene signatures that were unique to the 
treatment of safingol/C2-ceramide combination in both U937 and NB4 cell lines. 
 
1) Early gene signatures in NB4 and U937 cells treated for 6h and 12h, 
respectively. 
 
2) Late gene signatures in NB4 and U937 cells treated for 12h and 24h, 
respectively. 
Transcripts 
Cluster Id Regulation Gene symbol FC (U937) FC (NB4) 
8101429 down PLAC8 2.58039 1.74775 
8084219 up KLHL24 2.44313 1.70561 
8051030 down SLC5A6 2.06188 1.67298 
7934898 down ANKRD22 2.0343 1.91826 
7978132 down IPO4 1.87923 1.81368 
8110569 up SQSTM1 1.85647 1.71273 
7904364 down WDR3 1.83608 1.83115 
8044473 down POLR1B 1.79983 1.62969 
8005475 up TRIM16L 1.75331 1.61241 
8147548 down POP1 1.75266 1.61622 
7926677 up OTUD1 1.74962 2.43724 
8050689 down C2orf44 1.71727 1.63574 
7940349 down CCDC86 1.67403 1.66573 
8086880 down CDC25A 1.66228 1.60004 
8001764 down GOT2 1.65772 1.6232 
7959052 down RFC5 1.61236 1.63562 
8012856 down ELAC2 1.61013 1.64019 
Transcripts 
Cluster Id Regulation Gene symbol FC (U937) FC (NB4) 
7951977 up FXYD6 1.709 1.7007 
8163063 down CTNNAL1 1.70758 2.00702 
7959623 down GTF2H3 1.69975 2.71503 
7927936 down DDX21 1.68636 2.02602 
7930226 down PDCD11 1.6286 2.3083 
8003298 down SLC7A5 1.62774 1.60356 
7951467 down ALKBH8 1.6269 2.40982 
7909745 down KCTD3 1.61004 2.28641 
7935146 down NOC3L 1.60797 2.77901 
7966462 down NAA25 1.60679 2.40736 
8107769 down SLC12A2 1.60052 2.74015 
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7948898 down SNORD31|SNHG1 2.12698 1.6229 
8005957 down SNORD4B 2.00382 1.64792 
7915640 down EIF2B3 1.87131 2.43456 
8008517 down NME1|NME1-NME2 1.86437 2.79522 
7935146 down NOC3L 1.85916 2.77901 
8158998 down SNORD36C|SNORD36A|RPL7A 1.85065 2.26678 
8097335 down HSPA4L 1.84896 2.35283 
8100347 down SCFD2 1.80043 1.93757 
7930226 down PDCD11 1.79169 2.3083 
7942064 down GAL 1.7768 2.12631 
8091243 down PCOLCE2 1.77148 1.64366 
7995825 up MT1F 1.77093 1.67026 
7999903 down C16orf88 1.76018 1.68305 
8143905 down ABCF2 1.75932 2.07616 
7922410 down SNORD44 1.75222 2.39636 
8112841 down HOMER1 1.75156 2.83947 
7981724 up IGHD|IGHG1 1.74958 2.16731 
7940182 up OR4D10|OR4D11|OR4D9 1.73816 2.37791 
7901091 down TOE1 1.73328 1.71401 
7926259 down MCM10 1.73146 2.0231 
7977820 down PRMT5 1.71821 2.17464 
7966462 down NAA25 1.71237 2.40736 
8121515 down SLC16A10 1.70174 1.9349 
7900510 down CTPS 1.69003 1.9979 
8155268 down POLR1E 1.68988 2.69668 
7915170 down MYCBP 1.68589 1.66601 
8019376 down DUS1L 1.68449 1.93143 
7958666 down C12orf24|GPN3 1.68027 2.63723 
8162880 down MRPL50 1.67855 2.35939 
8004694 down CYB5D1 1.67405 1.73934 
7970473 down XPO4 1.66999 2.32698 
8086880 down CDC25A 1.66228 1.72128 
8139392 down DDX56 1.65559 1.95684 
8066461 down TOMM34 1.65555 1.94321 
8048370 down BCS1L 1.64688 1.95491 
7969533 down SLAIN1 1.64603 1.88823 




Supplementary Table 2. The lists of gene sets that were enriched in U937 and 
NB4 cell treated with free safingol/C2-ceramide combinationa.  
8105191 down PARP8 1.64556 1.78548 
8151471 down MRPS28|TPD52 1.64355 3.24688 
7959623 down GTF2H3 1.64033 2.71503 
7924969 down TAF5L 1.63729 1.87075 
8148317 down MYC 1.63631 1.77106 
8043413 down RPIA 1.63609 1.93861 
8030113 down RUVBL2 1.63428 1.93236 
7992917 down CLUAP1 1.6342 1.82562 
7989915 down TIPIN 1.63403 2.0058 
8128606 down RTN4IP1 1.63272 1.87998 
7988077 down LCMT2 1.62005 1.63434 
8075406 down PES1 1.61481 1.74994 
8038261 down GYS1 1.61315 1.70625 
NAME NES (Earlyb) 
NES 
(Latec) 
MANALO_HYPOXIA_DN -3.48 -3.87 
MORF_AATF -3.14 -3.62 
WONG_EMBRYONIC_STEM_CELL_CORE -3.10 -3.58 
MORF_BUB3 -3.09 -3.64 
PUJANA_XPRSS_INT_NETWORK -3.08 -3.40 
MORF_XRCC5 -3.05 -3.46 
MORF_GNB1 -3.05 -3.47 
MORF_PRKDC -3.04 -3.48 
MORF_HDAC2 -3.03 -3.67 
MORF_RAD23A -3.03 -3.56 




MORF_EIF3S2 -3.00 -3.44 
PUJANA_BRCA_CENTERED_NETWORK -2.99 -3.20 
MORF_FBL -2.97 -3.35 
REACTOME_CELL_CYCLE_CHECKPOINTS -2.97 -3.39 
FUJII_YBX1_TARGETS_DN -2.96 -3.10 
MORF_DDB1 -2.96 -3.24 
GARY_CD5_TARGETS_DN -2.96 -3.65 
REACTOME_S_PHASE -2.95 -3.28 
MORF_PPP1CA -2.95 -3.24 
MORF_HDAC1 -2.92 -3.40 
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MORF_PHB -2.92 -2.97 
REACTOME_G1_S_TRANSITION -2.92 -3.20 
REACTOME_SYNTHESIS_OF_DNA -2.91 -3.25 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP -2.91 -3.36 
REACTOME_DNA_REPLICATION_PRE_INITIATION -2.91 -3.25 
MORF_G22P1 -2.91 -3.33 
REACTOME_MITOTIC_M_M_G1_PHASES -2.90 -3.41 
MORF_PPP1CC -2.89 -3.55 
KOBAYASHI_EGFR_SIGNALING_24HR_DN -2.89 -3.22 
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C -2.89 -3.25 
GNF2_MCM5 -2.88 -3.01 
PUJANA_BRCA2_PCC_NETWORK -2.87 -3.32 
MUELLER_PLURINET -2.87 -3.15 
MORF_RFC4 -2.87 -3.47 
MORF_CSNK2B -2.87 -3.32 




REACTOME_METABOLISM_OF_RNA -2.86 -3.29 
GNF2_RAN -2.85 -3.32 
REACTOME_SNRNP_ASSEMBLY -2.85 -3.19 
MORF_HAT1 -2.84 -3.48 
MORF_RAD54L -2.84 -3.18 
GNF2_SMC4L1 -2.83 -3.09 
MORF_SOD1 -2.83 -3.55 
MORF_PRKAG1 -2.83 -3.25 
ELVIDGE_HYPOXIA_DN -2.83 -3.08 
MORF_ANP32B -2.83 -3.20 
MITSIADES_RESPONSE_TO_APLIDIN_DN -2.82 -3.54 




MORF_RPA2 -2.82 -3.21 
MORF_DAP3 -2.82 -3.31 
REACTOME_MRNA_SPLICING -2.81 -3.23 
REACTOME_DNA_REPAIR -2.81 -3.06 
SCHUHMACHER_MYC_TARGETS_UP -2.81 -3.24 
MORF_RRM1 -2.81 -3.27 




SONG_TARGETS_OF_IE86_CMV_PROTEIN -2.81 -2.85 




MORF_PCNA -2.80 -3.04 
GNF2_RFC4 -2.80 -3.02 
MORF_CTBP1 -2.79 -3.20 








ZHANG_RESPONSE_TO_CANTHARIDIN_DN -2.77 -3.00 
REACTOME_M_G1_TRANSITION -2.76 -3.11 
KAUFFMANN_DNA_REPAIR_GENES -2.75 -3.10 




RNA_PROCESSING -2.74 -3.29 




REACTOME_HIV_LIFE_CYCLE -2.73 -3.35 
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN -2.73 -2.78 




MOOTHA_MITOCHONDRIA -2.73 -3.18 
MORF_MAP2K2 -2.73 -3.09 




FOURNIER_ACINAR_DEVELOPMENT_LATE_2 -2.72 -3.22 





REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE -2.71 -3.38 
MORF_AP2M1 -2.71 -3.07 
RIBONUCLEOPROTEIN_COMPLEX -2.71 -3.01 
GNF2_RRM1 -2.70 -3.17 
WONG_MITOCHONDRIA_GENE_MODULE -2.70 -3.23 
GNF2_APEX1 -2.70 -3.13 
MODULE_244 -2.70 -2.93 
ORGANELLE_LUMEN -2.70 -3.30 
ZHANG_BREAST_CANCER_PROGENITORS_UP -2.70 -3.48 
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MEMBRANE_ENCLOSED_LUMEN -2.69 -3.27 
MORF_ERH -2.69 -3.18 
MITOCHONDRIAL_PART -2.69 -3.09 
MORF_ACP1 -2.68 -3.21 
CROONQUIST_IL6_DEPRIVATION_DN -2.68 -2.89 
GNF2_MCM4 -2.67 -3.01 







MORF_PSMC1 -2.66 -3.30 
NUCLEOLUS -2.66 -3.06 
REACTOME_G2_M_CHECKPOINTS -2.66 -3.00 
KAUFFMANN_MELANOMA_RELAPSE_UP -2.65 -2.91 
ELVIDGE_HIF1A_TARGETS_UP -2.65 -3.10 
BERENJENO_TRANSFORMED_BY_RHOA_UP -2.64 -3.22 
PAL_PRMT5_TARGETS_UP -2.64 -2.99 
MORF_UNG -2.64 -3.07 




GNF2_PA2G4 -2.64 -3.26 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 -2.64 -3.26 







MORF_RAD21 -2.63 -3.32 
REN_BOUND_BY_E2F -2.63 -2.85 




MORF_CDC10 -2.62 -3.01 




MODULE_125 -2.62 -2.79 
MORF_ESPL1 -2.61 -2.95 
MODULE_158 -2.61 -2.77 
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GNF2_PCNA -2.61 -3.01 




MISSIAGLIA_REGULATED_BY_METHYLATION_DN -2.60 -2.74 
MORF_MSH2 -2.60 -2.99 
MODULE_54 -2.60 -2.98 
MORF_SKP1A -2.60 -3.28 
RNA_SPLICING -2.60 -2.84 
MODULE_252 -2.59 -3.05 
GNF2_RFC3 -2.59 -2.70 







NUCLEAR_LUMEN -2.59 -3.18 
MORF_CDK2 -2.58 -2.85 
MORF_SMC1L1 -2.58 -2.90 
REACTOME_ELECTRON_TRANSPORT_CHAIN -2.58 -2.77 
KEGG_DNA_REPLICATION -2.58 -2.65 




BENPORATH_ES_2 -2.57 -2.31 
MODULE_57 -2.57 -2.93 
REACTOME_MRNA_SPLICING_MINOR_PATHWAY -2.57 -2.78 




RUIZ_TNC_TARGETS_DN -2.57 -2.76 
GNF2_FEN1 -2.57 -2.86 
REACTOME_STABILIZATION_OF_P53 -2.57 -2.82 

















MOOTHA_VOXPHOS -2.54 -2.78 
MORF_PTPN11 -2.54 -3.12 
MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP -2.54 -2.96 
KEGG_PROTEASOME -2.54 -2.76 
DANG_MYC_TARGETS_UP -2.54 -2.92 
MORF_PRDX3 -2.54 -3.06 
MORF_AP3D1 -2.54 -3.06 
REACTOME_SIGNALING_BY_WNT -2.54 -2.88 
MORF_MTA1 -2.53 -2.81 










ELVIDGE_HYPOXIA_BY_DMOG_DN -2.53 -2.47 
MORF_USP5 -2.53 -2.81 








MORF_RAD23B -2.52 -3.25 
PUJANA_BREAST_CANCER_LIT_INT_NETWORK -2.52 -2.84 
WHITEFORD_PEDIATRIC_CANCER_MARKERS -2.52 -2.82 
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN -2.51 -3.28 




BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP -2.51 -3.36 
GNF2_CCNA2 -2.51 -2.87 
MORF_BMI1 -2.51 -2.76 
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN -2.51 -3.14 















GNF2_CENPF -2.49 -2.92 
MODULE_98 -2.49 -2.98 
KEGG_PYRIMIDINE_METABOLISM -2.49 -2.75 




MORF_RPA1 -2.49 -2.92 
MRNA_METABOLIC_PROCESS -2.49 -2.97 
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP -2.49 -2.65 
MORF_CUL1 -2.48 -2.99 
MODULE_91 -2.48 -2.86 




PENG_RAPAMYCIN_RESPONSE_DN -2.47 -2.79 
MITOCHONDRIAL_MATRIX -2.47 -2.62 
DANG_REGULATED_BY_MYC_UP -2.47 -2.67 
MITOCHONDRIAL_LUMEN -2.47 -2.66 
BENPORATH_PROLIFERATION -2.47 -3.15 
MITOCHONDRIAL_MEMBRANE_PART -2.47 -2.73 
MORF_CDC16 -2.46 -2.93 
MARKEY_RB1_ACUTE_LOF_DN -2.46 -2.78 
MODULE_124 -2.46 -3.11 
KANG_DOXORUBICIN_RESISTANCE_UP -2.46 -2.78 
GNF2_CKS1B -2.46 -2.76 
CHANG_CORE_SERUM_RESPONSE_UP -2.46 -2.69 
MODULE_403 -2.46 -2.71 




REACTOME_METABOLISM_OF_CARBOHYDRATES -2.44 -2.65 




MORF_RAC1 -2.44 -3.11 
REACTOME_HIV1_TRANSCRIPTION_ELONGATION -2.44 -2.70 
RIZ_ERYTHROID_DIFFERENTIATION -2.44 -2.48 
MORF_FEN1 -2.44 -2.99 
DNA_REPLICATION -2.43 -2.67 
MITOCHONDRIAL_MEMBRANE -2.43 -2.83 
MORF_RAF1 -2.43 -3.00 
MORF_PPP2CA -2.43 -3.07 
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LY_AGING_OLD_DN -2.43 -2.70 
MODULE_28 -2.43 -2.80 
DNA_REPAIR -2.43 -2.83 
MODULE_151 -2.42 -3.04 
SGCGSSAAA_V$E2F1DP2_01 -2.42 -2.26 
GCM_APEX1 -2.42 -2.84 
IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR -2.42 -2.79 
KEGG_PARKINSONS_DISEASE -2.42 -2.53 
MORF_DEAF1 -2.42 -2.91 
MODULE_219 -2.42 -2.85 
GNF2_CDC2 -2.42 -2.84 
GNF2_ELAC2 -2.42 -2.71 
MORF_TPR -2.42 -2.93 
BASAKI_YBX1_TARGETS_UP -2.42 -2.69 
REACTOME_MITOTIC_PROMETAPHASE -2.41 -2.92 
MODULE_77 -2.41 -2.61 
MITOCHONDRIAL_ENVELOPE -2.41 -2.81 
MORF_RFC1 -2.41 -2.84 
GCM_CBFB -2.40 -2.85 




GNF2_MSH2 -2.40 -2.53 
KEGG_OXIDATIVE_PHOSPHORYLATION -2.40 -2.51 
ORGANELLE_ENVELOPE -2.40 -3.05 
MITOCHONDRIAL_INNER_MEMBRANE -2.39 -2.62 
PROTEIN_FOLDING -2.39 -2.54 
MORF_BUB1B -2.39 -3.04 
MORF_GSPT1 -2.39 -2.87 
DNA_RECOMBINATION -2.39 -2.42 
GNF2_XRCC5 -2.39 -2.99 
ENVELOPE -2.39 -3.07 




REACTOME_TRANSCRIPTION_COUPLED_NER -2.38 -2.61 
MORF_PPP5C -2.38 -2.43 
ORGANELLE_INNER_MEMBRANE -2.38 -2.61 




MODULE_114 -2.37 -3.04 
KEGG_BASE_EXCISION_REPAIR -2.37 -2.36 
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MORF_PRKAR1A -2.37 -2.95 
KEGG_NUCLEOTIDE_EXCISION_REPAIR -2.37 -2.55 
NUCLEAR_PORE -2.36 -2.74 
MODULE_102 -2.36 -2.64 




REACTOME_MRNA_3_END_PROCESSING -2.36 -2.57 
BASSO_B_LYMPHOCYTE_NETWORK -2.35 -2.80 




BIDUS_METASTASIS_UP -2.35 -3.20 
GNF2_SMC1L1 -2.35 -2.47 
GNF2_RRM2 -2.35 -2.68 
V$E2F1_Q4_01 -2.35 -2.35 
GNF2_HAT1 -2.35 -2.69 
MATTIOLI_MGUS_VS_PCL -2.35 -2.44 
GCM_CSNK2B -2.34 -2.57 
GNF2_CKS2 -2.34 -2.79 
MOHANKUMAR_TLX1_TARGETS_UP -2.34 -2.88 
GNF2_CCNB2 -2.34 -2.81 
MORF_EIF3S6 -2.34 -2.89 
CELL_CYCLE_PROCESS -2.34 -2.66 




POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN -2.33 -2.61 
GRADE_COLON_AND_RECTAL_CANCER_UP -2.33 -3.05 




MORF_PAPSS1 -2.33 -2.88 
WAKASUGI_HAVE_ZNF143_BINDING_SITES -2.33 -2.83 
GNF2_HMMR -2.33 -2.77 
GCM_PPP1CC -2.33 -2.60 
V$E2F_Q6_01 -2.32 -2.32 
HORIUCHI_WTAP_TARGETS_DN -2.32 -3.17 
V$E2F_Q3_01 -2.32 -2.30 
KAUFFMANN_DNA_REPLICATION_GENES -2.32 -2.50 
V$E2F1_Q6 -2.32 -2.41 
PYEON_HPV_POSITIVE_TUMORS_UP -2.32 -2.08 
MORF_TERF2IP -2.32 -2.85 
 177 
 
V$E2F1_Q6_01 -2.32 -2.41 







DNA_DEPENDENT_DNA_REPLICATION -2.32 -2.60 
NUCLEOPLASM -2.31 -2.97 
GNF2_FBL -2.31 -2.96 
GNF2_MSH6 -2.31 -2.76 
GNF2_G22P1 -2.31 -2.68 
CELL_CYCLE_PHASE -2.31 -2.62 











PORE_COMPLEX -2.30 -2.73 
GNF2_HDAC1 -2.29 -2.93 
GGAANCGGAANY_UNKNOWN -2.29 -2.28 
M_PHASE_OF_MITOTIC_CELL_CYCLE -2.29 -2.69 
PROTEASOME_COMPLEX -2.29 -2.69 




MODULE_42 -2.29 -2.49 
MORF_PPP2R4 -2.28 -2.46 
GKCGCNNNNNNNTGAYG_UNKNOWN -2.28 -2.65 
REACTOME_LAGGING_STRAND_SYNTHESIS -2.28 -2.19 
KEGG_RNA_POLYMERASE -2.28 -2.62 
REACTOME_GLUCOSE_TRANSPORT -2.28 -2.73 
NUCLEOPLASM_PART -2.27 -2.87 
MORF_TERF1 -2.27 -2.55 
GNF2_CDC20 -2.27 -2.77 







MORF_NME2 -2.26 -2.83 
GNF2_ESPL1 -2.26 -2.58 
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MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN -2.26 -2.42 
MORF_BUB1 -2.25 -2.96 
FURUKAWA_DUSP6_TARGETS_PCI35_DN -2.25 -2.50 
REACTOME_CITRIC_ACID_CYCLE -2.25 -2.36 
HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP -2.25 -2.62 
MULLIGHAN_MLL_SIGNATURE_2_UP -2.25 -2.16 
REACTOME_GLOBAL_GENOMIC_NER -2.25 -2.35 
MORF_ATOX1 -2.25 -2.54 
GNF2_BUB1 -2.25 -2.48 
KIM_MYC_AMPLIFICATION_TARGETS_UP -2.25 -2.74 
CHANG_CYCLING_GENES -2.25 -2.31 
V$E2F_02 -2.24 -2.31 




V$GABP_B -2.24 -2.74 
REACTOME_MRNA_PROCESSING -2.24 -2.46 
GNF2_CENPE -2.24 -2.65 
MODULE_83 -2.24 -2.99 
BILD_MYC_ONCOGENIC_SIGNATURE -2.24 -2.51 
KEGG_HUNTINGTONS_DISEASE -2.24 -2.56 







GCM_AIP -2.23 -2.46 




REACTOME_G2_M_TRANSITION -2.23 -2.57 
GCM_ING1 -2.22 -2.50 
KEGG_RNA_DEGRADATION -2.22 -2.58 




MORF_RAB1A -2.22 -2.86 
V$E2F4DP2_01 -2.22 -2.32 
METHYLTRANSFERASE_ACTIVITY -2.22 -2.39 
V$E2F_Q6 -2.22 -2.36 
SPLICEOSOME -2.22 -2.39 
V$E2F1DP1_01 -2.21 -2.32 
V$E2F4DP1_01 -2.21 -2.25 
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V$E2F1DP2_01 -2.21 -2.31 
GCM_HDAC1 -2.21 -2.38 




MODULE_32 -2.20 -2.98 
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP -2.20 -2.71 
STEIN_ESRRA_TARGETS_UP -2.20 -2.52 
MORF_SART1 -2.20 -2.64 
DAIRKEE_TERT_TARGETS_UP -2.20 -2.25 
MOOTHA_PGC -2.20 -2.57 
GNF2_NPM1 -2.20 -2.75 
MODULE_278 -2.20 -2.46 
MORI_LARGE_PRE_BII_LYMPHOCYTE_UP -2.20 -2.56 
ACTAYRNNNCCCR_UNKNOWN -2.19 -2.70 




BORCZUK_MALIGNANT_MESOTHELIOMA_UP -2.19 -3.22 
MORF_GMPS -2.19 -2.75 
REACTOME_METABLISM_OF_NUCLEOTIDES -2.19 -2.50 
REACTOME_TRANSCRIPTION -2.19 -2.49 




REACTOME_APOPTOSIS -2.18 -2.65 
MORF_FANCG -2.18 -2.23 
V$E2F_03 -2.18 -2.22 








FAELT_B_CLL_WITH_VH3_21_UP -2.17 -2.00 
MODULE_308 -2.17 -2.50 
REACTOME_CENTROSOME_MATURATION -2.17 -2.44 
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 -2.17 -2.37 
BIOCARTA_MCM_PATHWAY -2.17 -2.58 
STEIN_ESRRA_TARGETS -2.17 -2.53 







JIANG_VHL_TARGETS -2.17 -2.01 
GALE_APL_WITH_FLT3_MUTATED_UP -2.16 -2.40 
KEGG_N_GLYCAN_BIOSYNTHESIS -2.16 -2.56 
PENG_LEUCINE_DEPRIVATION_DN -2.16 -2.43 
KEGG_HOMOLOGOUS_RECOMBINATION -2.16 -1.94 
ALCALAY_AML_BY_NPM1_LOCALIZATION_DN -2.16 -2.17 
GCM_ACTG1 -2.16 -2.91 
MODULE_397 -2.16 -2.15 




NUCLEAR_CHROMOSOME -2.16 -2.15 
MULLIGHAN_MLL_SIGNATURE_1_UP -2.16 -2.21 
MODULE_126 -2.16 -2.70 




V$E2F1_Q3 -2.15 -2.03 
RESPONSE_TO_DNA_DAMAGE_STIMULUS -2.15 -2.72 
TRANSLATION_REGULATOR_ACTIVITY -2.15 -2.66 




RAMALHO_STEMNESS_UP -2.15 -3.02 
BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP -2.15 -2.52 
ATP_DEPENDENT_RNA_HELICASE_ACTIVITY -2.15 -2.29 
MENSSEN_MYC_TARGETS -2.15 -2.23 




MODULE_337 -2.14 -2.55 
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN -2.14 -2.82 
TMTCGCGANR_UNKNOWN -2.14 -2.51 
MORF_PSMC2 -2.14 -3.01 
REACTOME_DOUBLE_STRAND_BREAK_REPAIR -2.14 -2.49 
MORI_IMMATURE_B_LYMPHOCYTE_DN -2.14 -2.40 
MORF_SS18 -2.14 -2.66 
KEGG_OOCYTE_MEIOSIS -2.13 -2.31 
JIANG_HYPOXIA_CANCER -2.13 -1.95 
V$E2F1DP1RB_01 -2.13 -2.13 
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a p<0.01; FDR<0.05; Maximum entries= 500 
b NB4 and U937 cells treated for 6h and 12h, respectively. 





LIN_APC_TARGETS -2.13 -1.79 
COLDREN_GEFITINIB_RESISTANCE_UP -2.13 -2.49 
GNF2_TTK -2.12 -2.66 
GNF2_SMC2L1 -2.12 -2.59 
DAIRKEE_CANCER_PRONE_RESPONSE_BPA -2.12 -2.36 
MODULE_388 -2.12 -2.28 
REGULATION_OF_CELL_CYCLE -2.12 -1.59 




GCM_CHUK -2.11 -2.70 
V$E2F_Q4 -2.11 -2.40 
RNA_DEPENDENT_ATPASE_ACTIVITY -2.11 -2.24 
REACTOME_METABOLISM_OF_AMINO_ACIDS -2.11 -2.31 
GNF2_H2AFX -2.10 -2.62 
REACTOME_MICRORNA_BIOGENESIS -2.10 -2.46 
RNA_BINDING -2.10 -2.77 
MORF_REV3L -2.10 -2.63 
MORF_IKBKG -2.10 -1.81 
MAYBURD_RESPONSE_TO_L663536_DN -2.10 -2.26 
KEGG_MISMATCH_REPAIR -2.10 -2.25 
AMUNDSON_GAMMA_RADIATION_RESPONSE -2.10 -2.32 
GNF2_BUB3 -2.10 -2.38 
RIBONUCLEASE_ACTIVITY -2.10 -2.08 







DAMAGED_DNA_BINDING -2.09 -2.16 
KEGG_ALZHEIMERS_DISEASE -2.09 -2.26 
GNF2_NS -2.09 -2.87 


















Supplementary Figure 4. GSEA-derived heat maps of 5 selected cell cycle-related 
gene sets highly enriched in U937 and NB4 cells treated with free safingol/C2-
ceramide combination. (A) Early signatures where NB4 and U937 cells treated for 
6h and 12h, respectively. (B) Late signatures where NB4 and U937 cells treated 
for 12h and 24h, respectively. (C) Full view of heat maps for early signatures. (D) 
Full view of heat maps for late signatures. Signal intensities are illustrated by 
colors, where the range of colors (red, pink, light blue, dark blue) shows the range 
of expression values (high, moderate, low, lowest). 
 
(A) (B) (C) (D) 
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Supplementary Figure 5. Effects of ( ♦) free safingol/C2-ceramide combination 
and ( ■) liposomal safingol/C2-ceramide treatment in various AML cell lines 
representing different subtypes, (A) KG-1-M1, (B) HL-60-M2, (C)NB4-M3, 
(D)U937-M5, (E) MV4-11-M5 and (F) HEL-M6, as well as (G) K562, a cell line 
of blast crisis of chronic myelogenous leukemia (BC-CML) Cells were exposed to 
various concentrations of each formulation for 72h, and viability was determined 





Supplementary Figure 6. Cytotoxicity of liposomal safingol/C2-ceramide in 
primary AML cell samples from ten patients. Cells were exposed to liposomal 
safingol/C2-ceramide (1.25µM - 20µM) for 72 h. Cell viability was determined 
by MTT assay. Data are mean ± S.D. obtained from one independent experiment 
done in triplicates. 
